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1.1. The family of “A Disintegrin And Metalloproteases” 
Proteolysis represents a crucial regulatory mechanism for cells. It plays a role in irreversible 
modifications of proteins and controls protein function. This includes post-translational modifi-
cations, such as removal of signal sequences and maturation of precursor proteins, activation 
and deactivation of enzymes and receptors and processing of cytokines and growth factors. The 
latter are often mediated by family members of  “A Disintegrin And Metalloproteases” 
(ADAMs). ADAMs are typical type-I transmembrane glycoproteins which cleave the 
ectodomains of type-I and type-II transmembrane or glycosylphosphatidylinositol- (GPI-) 
anchored proteins (Reiss and Saftig, 2009). This process is referred to as “shedding” (Figure 3). 
Shedding takes place in every cell type. The substrates are cleaved in close proximity to the 
transmembrane domain. The resulting ectodomains as well as the membrane bound stubs exhib-
it diverse and crucial effects of ADAM-functions. For instance, shed growth factors like TGF-α 
induce proliferation in a paracrine and autocrine manner by activating the epidermal growth 
factor receptor (EGFR). The most important sheddases belong to the ADAM family and will be 
introduced in this chapter. 
 
1.1.1. Classification & Members 
ADAMs are zinc-dependent-metalloproteinases and belong to the group of metzincins (Wolfs-
berg et al., 1995). This protease family shares a highly conserved zinc-binding amino acid se-
quence (HExxHxxGxxH) with three histidines in their catalytically active center. C-terminal, 
this motif is followed by a methionine turn (Bode et al., 1993). Metzincins are divided in four 
groups: matrix-metalloproteases (MMPs), astacines, serralysines and adamalysines (Figure 1). 
ADAMs are assigned to the adamalysines in the MEROPS classification (Rawlings et al., 
2008). Adamalysines include also the protease families “a disintegrin and metalloproteinase 
with thrombospondin motifs” (ADAMTSs) and snake venom metalloproteases (SVMPs).  
ADAM proteases have been identified in many species, inter alia in the nematode Caenorhabdi-
tis elegans, the fruit fly Drosophila melanogaster, the fission yeast Schizosaccharomyces pombe 
and in all investigated vertebrates (Blobel, 1997; Edwards et al., 2008; Wolfsberg and White, 
1996). Thirteen family members of the so far identified 21 human members are proteolytically 
active (ADAMDEC-1, ADAM-8, -9, -10, -12, -15, -17, -19, -20, -21, -28, -30 and 33).  The 
others lack one or more features in the active Zn2+-binding site and may rather play a role in 
protein-protein interaction than proteolysis. Within the group of the proteolytic active members 
Introduction  
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ADAM10 and -17 are most extensively studied due to their crucial physiological importance 




Figure 1: Metzincin family of Zn2+-dependent metalloproteases. The superfamily of metzincins con-
sist of matrix metalloproteases (MMPs), astacines, serralysines and adamalysines. The “a disintegrin and 
metalloproteases” (ADAMs) are assigned to the group of adamalysines together with snake venom me-
talloproteases (SVMPs) and “ a disintegrin and metalloprotease with thrombospondin motifs” (AD-
AMTSs)(Rawlings et al. 2008). 
 
 
1.1.2. Structure of ADAM17 and ADAM10 
ADAMs consists of a typical sequence of protein domains. Most ADAMs possess a signal se-
quence at their N-terminus, followed by a pro-domain, a metalloprotease domain, a disintegrin 
domain, a cysteine-rich region, a EGF-like domain, a transmembrane domain and a cytoplasmic 
tail (Figure 2)(Stone et al., 1999). ADAM10 and -17 are atypical members of this family; they 
contain a pro-, catalytic- disintegrin- and a membrane proximal domain with a α/β fold and a 
stalk region followed by a transmembrane domain and a cytoplasmic tail (Figure 2) (Düsterhöft 
et al., 2014; Lorenzen et al., 2012; S. Takeda, 2009). 
The signal sequence directs the ADAM to the secretory pathway and is cleaved off afterwards. 
The pro-domain acts as an intramolecular chaperone and keeps the enzyme inactive until it is 
removed by a furin type pro-protein convertase (Lum et al., 1998; Roghani et al., 1999; Schlön-
dorff et al., 2000). Recent studies suggest that ADAM17 is still able to cleave its substrate at the 
cell surface with an intact pro-domain (Lum et al., 1998; Roghani et al., 1999; Schwarz et al., 
2013a). However removal of the pro-domain generally occurs during the transit through the 









Figure 2: Schematic view of the domain structure of ADAMs in general and ADAM10 and -17. The 
catalytic active members of the ADAM family consist of a signal sequence (not shown), a prodomain, a 
metalloprotease-, a disintegrin-, a cysteine-rich-, a transmembrane- and a cytoplasmic domain. ADAM10 
and -17 have instead of the cysteine-rich and EGF-like domain, a membrane proximal domain and a flex-
ible stalk. The flexible stalk of ADAM17 have been named “conserved ADAM seventeen dynamic inter-
action sequence” (CANDIS) (Düsterhöft et al., 2014). 
 
A disintegrin domain follows the metalloprotease domain. The disintegrin domain of ADAM17 
promotes cell-cell contacts and adhesion through binding to α5β1-integrins (White, 2003). 
Integrins are transmembrane receptors linking the cytoskeleton to the extracellular matrix 
(ECM), thus providing cell adhesiveness. Several members of the ADAM family bind to 
integrins (Arribas et al., 2006). The binding of ADAM17 to integrins results in a steric inhibi-
tion (Trad et al., 2013).  Although ADAM10 contains a disintegrin domain, it is unclear if 
ADAM10 binds to integrins.  
The membrane proximal domain (MPD) and the stalk region of ADAM17 play important roles 
in multimerisation, substrate recognition and activity regulation (Lorenzen et al., 2012; 2011). 
Interestingly, the MPD and the stalk region bind only to the type I transmembrane proteins 
IL1RII and IL6R and not to the type II transmembrane proteins pro-TNF-α and TNFRII (Düs-
terhöft et al., 2013; Lorenzen et al., 2012). These first studies on the role of the MPD did not 
distinguish between the stalk region and the MPD. The recently defined MPD (amino acids 581-
642) contains 10 cysteines with one thioredoxin motif (C600XXC603), which are targets for pro-
tein-disulfide isomerases (PDIs) (Düsterhöft et al., 2013). PDIs catalyze breaking and formation 
of disulfide-bonds between cysteines. Within the MPD, three cysteine-bridges can be reshuf-
fled. This restructuring leads to a conformational change of the MPD from a flexible (ac-
tive/open) form to an inflexible (inactive/closed) form (Düsterhöft et al., 2013). It was shown 


















































General ADAM domain structure:

























































al., 2000; Willems et al., 2010). The small stalk region of ADAM17 is named “conserved AD-
AM seventeen dynamic interaction sequence” (CANDIS, amino acids 643-671) and consists of 
highly conserved amino acids, which form a α-helical structure. This domain contributes to 
IL6R-, but not to TNF-α interaction (Düsterhöft et al., 2014).  
The transmembrane region of ADAM17 is an α-helical structure and is also involved in the 
function. A GPI-anchored ADAM17 construct lacking the transmembrane domain (TMD) loses 
its ability to shed TGF-α, TNF-α and L-selectin (X. Li et al., 2007). In addition, replacement of 
the TM domain of ADAM17 with the transmembrane region of PDGFR (Platelet derived 
growth factor receptor), restored the ability to shed TNF-α and L-selectin but not TGF-α (X. Li 
et al., 2007). These findings indicate that the TM domain is involved in substrate recognition 
but the mechanism is still unclear.  
The intracellular part of ADAM17, the cytotail, contains phosphorylation- and a SH3-binding 
sites, which might play a role in activity regulation, transport and localization (Schwarz et al., 
2013b; P. Xu and Derynck, 2010). Interestingly, deletion mutants of the ADAM17 cytotail are 
still fully functional (Le Gall et al., 2010). 
Less is known about the structure-function relationship of ADAM10. The structural organiza-
tion is comparable to its close relative ADAM17. The cytoplasmic tail of ADAM10 is dispensa-
ble for stimulated shedding, but exhibits an inhibitory effect on constitutive shedding (Maretzky 
and Evers et al. manuscript in preparation). Furthermore, the cytoplasmic tail of ADAM10 may 
play a role in transport and localization, as it contains sorting signals and binding sites for inter-
action partners (Marcello et al., 2013; Wild-Bode et al., 2006).  
Taken together, still many questions regarding to the structure-function relationship of AD-
AM10 and -17 remain unanswered. Nevertheless each domain of ADAM10 and -17 contributes 
to the protease function by either regulating the proteolytic activity directly, or by binding to 
substrates or integrins and probably also by regulating the proteases localization.  
 
 
1.2. Physiological roles of ADAM10 and ADAM17 
ADAM10 and -17 exert different physiological roles in health and disease and in embryonic 
development. They are expressed in all organs and cell types in different quantities and so are 
their substrates. The importance of ADAM10 and -17 in cell function and pathophysiology will 




Figure 3: Schematic view of ADAM10 and ADAM17-mediated substrate shedding: Depicted are the 
generalized shedding events of substrate A (such as an EGFR-ligand) and substrate B (such as a cell-
adhesion molecule) by ADAM10 or -17. Both proteases cleave their substrate in close proximity to the 
cell surface (MP: metalloprotease domain; Dis: disintegrin domain; MPD: membrane proximal domain; 
CANDIS: conserved ADAM17 dynamic interaction sequence; FS: flexible stalk; TM: transmembrane 
domain; CT: cytotail). 
 
1.2.1. Substrate diversity 
Several dozen substrates are identified for ADAM10 and -17 (Scheller et al., 2011). These sub-
strates include e.g. cytokines, growth factors, receptors and cell adhesion molecules. ADAM17 
was first described as “TNF-α converting enzyme” (TACE) due to its ability to shed pro-TNF-α 
and release this pro-inflammatory cytokine (Black et al., 1997; Moss et al., 1997). Some 
ADAM10 and -17 substrates, which are of special interest for this thesis, are listed in Table 1 
and Table 2. Several substrates are exclusively cleaved by one of the two proteases, like TNF-α 
by ADAM17 and E-cadherin by ADAM10, others can be cleaved by both proteases, such as 
APP and CX3CL1 (fractalkine) (Buxbaum et al., 1998; Christian, 2012; Hundhausen et al., 
2003; Lammich et al., 1999). ADAM10 or -17 substrates do not contain a specific consensus 
sequences in their cleavage site, but all substrates are shed close to the membrane. Nevertheless 
ADAM10 and -17 have preferences in their cleavage site specifity for some amino acids. While 
both cleave N-terminal of leucine, ADAM10 shows additional preferences towards aromatic 



















Table 1: Important ADAM10 substrates. 
Substrate	   Function	   Reference	  
Notch	   Development;	  tissue	  repair	   (Pan	  and	  Rubin,	  1997)	  
VE-­‐cadherin	   Cell-­‐cell	  adhesion	   (Schulz	  et	  al.,	  2008)	  
N-­‐cadherin	   Cell-­‐cell	  adhesion	   (Reiss	  et	  al.,	  2005)	  
CX3CL1	   Immunity	   (Hundhausen	  et	  al.,	  2003)	  
E-­‐cadherin	   Cell-­‐cell	  adhesion	   (Maretzky	  et	  al.,	  2005)	  
Betacellulin	   EGFR-­‐ligand,	  proliferation	   (Sahin	  et	  al.,	  2004)	  
APP	   Non	  amyloidogenic	  pathway	   (Lammich	  et	  al.,	  1999)	  
 
Table 2: Important ADAM17 substrates. 
Substrate	   Function	   Reference	  
TGF-­‐α	   EGFR-­‐ligand,	  proliferation	   (Sahin	  et	  al.,	  2004)	  
HB-­‐EGF	   EGFR-­‐ligand,	  proliferation	   (Sahin	  et	  al.,	  2004)	  
TNF-­‐α	   Pro-­‐inflammatory	  cytokine	   (Black	   et	   al.,	   1997),	   (Moss	   et	  
al.,	  1997)	  
IL6-­‐R	   Immunity	   (Garbers	  et	  al.,	  2011)	  
JAM-­‐A	   Cell-­‐cell	  adhesion	   (Koenen	  et	  al.,	  2009)	  
L-­‐selectin	   Cell-­‐cell	  adhesion,	  immunity	   (Hafezi-­‐Moghadam	   et	   al.,	  
2001)	  
TNFR1	   Immunity	   (D	  Alessio	  et	  al.,	  2012)	  
VEGFR	   Vasculogenesis,	  angiogenesis	   (Swendeman	  et	  al.,	  2008)	  
 
1.2.2. Cell adhesion and leukocyte transmigration 
One important feature of ADAM10 and -17 function is the ability to shed cell adhesion mole-
cules. Cell adhesion molecules (CAMs) are proteins connecting cells with the ECM and to other 
cells, maintaining organized structures of cells and tissues. CAMs include members of the Ig 
superfamily, cadherins, integrins and selectins. Several substrates of ADAM10 and -17 are clas-
sified to these groups, such as neuronal-, epithelial and vascular endothelial cadherins (N-, E-, 
and VE-cadherin), junctional adhesion molecule A (JAM-A) or leukocyte selectin (L-selectin). 
ADAM10-induced N- and E-cadherin cleavage results not only in dramatic changes in the adhe-
siveness of cells; it results also in a redistribution of β-catenin. This in turn results in β-catenin-
induced gene expression (Maretzky et al., 2005; Reiss et al., 2005). Furthermore, VE-cadherin 
shedding increases the permeability of endothelial cell monolayers and T-cell transmigration 
(Schulz et al., 2008).  
ADAM17 sheds the endothelial tight junction protein JAM-A after treatment with inflammatory 
cytokines (Koenen et al., 2009). The soluble JAM-A fragment blocks endothelial migration and 
transendothelial migration of neutrophils in vitro and decreases neutrophil infiltration in a mu-
rine air pouch model (Koenen et al., 2009). In this context of leukocyte transmigration, L-
selectin is involved in the binding and rolling of leukocytes to the endothelial wall. This pro-
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motes transendothelial migration of leukocytes to the site of inflammation. ADAM17-mediated 
shedding of L-selectin weakens the binding to endothelial cells and increases the velocity of 
rolling (Hafezi-Moghadam et al., 2001; Tang et al., 2011). In general, the shedding of adhesion 
molecules weakens not only cell adhesion and promotes leukocyte transmigrations, it also paves 
the way for cell migration and proliferation in development and tissue repair. 
  
1.2.3. EGFR signaling in proliferation and migration 
The tyrosine kinase epithelial growth factor receptor EGFR, also known as ERBB1, is one of 
the most versatile receptors. Several ligands for the EGFR are known (Table 3). All of them are 
expressed as membrane spanning proforms and are proteolytically released by ADAM10 or -17. 
This leads to autocrine and paracrine signaling (Blobel, 2005). EGFR signaling regulates many 
key processes in cell biology, such as proliferation, migration, survival and differentiation dur-
ing development, tissue homeostasis, repair and tumorigenesis (Yarden and Sliwkowski, 2001). 
An overview about ADAM-mediated transactivation of the EGFR is depicted in Figure 4. 
 
Table 3 EGFR Ligands: All EGFR-ligands are proteolytically released by either ADAM10 or AD-
AM17.  These ligands activate then EGFR-dependent signaling cascades. 
Substrate	   Protease	   Reference	  
Pro-­‐EGF	   ADAM10	   (Cohen,	  1965;	  Sahin	  et	  al.,	  2004)	  
Pro-­‐TGF-­‐α	   ADAM17	   (Derynck	  et	  al.,	  1984;	  Sahin	  et	  al.,	  2004)	  
Pro-­‐AREG	   ADAM17	   (Sahin	  et	  al.,	  2004;	  Shoyab	  et	  al.,	  1989)	  
Pro-­‐HB-­‐EGF	   ADAM17	   (Higashiyama	  et	  al.,	  1991;	  Sahin	  et	  al.,	  2004)	  
Pro-­‐BTC	   ADAM10	   (Sahin	  et	  al.,	  2004;	  Shing	  et	  al.,	  1993)	  
Pro-­‐Epigen	   ADAM17	  	   (Sahin	  and	  Blobel,	  2007;	  Strachan	  et	  al.,	  2001)	  
Pro-­‐Epiregulin	   ADAM17	   (Sahin	  et	  al.,	  2004;	  Toyoda	  et	  al.,	  1995)	  
 
Upon binding of a ligand, two receptor molecules dimerize (Ferguson et al., 2003; Ogiso et al., 
2002). Consequently, the cytoplasmic kinase domains are drawn near each other. As a result the 
cytoplasmic domains of each molecule are reciprocally phosphorylated (Xue and Lucocq, 
1998). This enables binding of the adaptor protein Grb-2 via SH2-domains. Grb-2 recruits SOS 
(son of sevenless), which binds to Grb2 (growth factor receptor-bound protein 2) via two do-
mains and activates Ras. Ras is a monomeric GTPase. The activated Ras induces a kinase cas-
cade, which amplifies and spreads the signal. This signaling cascade induces the activation of 
ERK1/2 (extracellular-signal regulated kinase). ERK is a “mitogen activated protein” (MAP) 
kinase which phosphorylates several transcription factors and other effector proteins leading to 







Figure 4: Transactivation of EGFR-signaling by ADAM-mediated growth factor shedding. Proteo-
lytic release of EGFR-ligands by ADAM10 or -17 activates EGFR-signalling. A process referred to as 
transactivation. Upon binding of the ligand, the intracellular kinase domains of the homodimer phosphor-
ylate each other and initiate a signaling cascade via GRB2, SOS, RAS, RAF, MEK and ERK1/2. Activat-
ed ERK1/2 phosphorylates several effector molecules including transcription factors. This induces for 
example proliferation and migration of the cells. 
 
1.2.4. Pathophysiology & disease models 
The importance of ADAM10 and -17 for (patho-) physiology and embryonic development be-
comes especially apparent with regard to mice models. Genetically modified mice and disease 
models provide a more holistic view in the function of these proteases. Mice which express an 
inactive variant of ADAM17 (taceΔZn/ΔZn) die between embryonic day 17.5 and birth (Peschon et 
al., 1998). T-cells derived from these mice fail to release TNF-α. Additionally, these mice phe-
notypically resemble TGF-α knockout mice, suggesting a crucial role of ADAM17 in EGFR 
signaling (Luetteke et al., 1993; Mann et al., 1993).  
The functions of ADAM17 in adult mice were investigated by using conditional knockouts. 
Mice lacking active ADAM17 in myeloid cells are protected from LPS-induced endotoxin 
shock. This is due to lower TNF-α serum levels compared to wildtype mice (Horiuchi et al., 
2007a). High serum levels of TNF-α are associated with rheumatoid arthritis, sepsis and other 
inflammatory pathologies (Zelová and Hošek, 2013). Mice expressing only ~5 % ADAM17 
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severe inflammation in a dextran sulfate sodium-induced colitis model. In that case the pheno-
type is caused by defective tissue repair as a consequence of impaired EGFR signaling (Chalaris 
et al., 2010). 
Mice lacking ADAM10 die at embryonal day 9.5 and show severe malformations in the nervous 
and cardiovascular system (Hartmann et al., 2002). The phenotypes of these mice have striking 
similarities with those that carry a Notch receptor deletion (Krebs et al., 2000). Conditional 
ADAM10 knockout mice lacking ADAM10 in neural precursor cells die prenatally. They have 
disrupted cortex and a reduced ganglionic eminence, caused by defective neuronal differentia-
tion (Jorissen et al., 2010). In vasculature, endothelial specific knockout of ADAM10 leads to 
increased branching and density of retinal vasculature which also recapitulates the phenotype 
observed in notch knockouts (Glomski et al., 2011). 
Taken together, the dominant effects of ADAM10 or -17 knockouts in vivo are mostly due to 
defective TNF-α and EGFR signaling for ADAM17 and Notch signaling for ADAM10. 
 
 
1.3. Regulation of ADAM10 and ADAM17 activity 
Several different mechanisms regulate the activity of ADAM10 and -17. This includes the ex-
pression, maturation and transport and the rapid activation of the shedding events. These mech-
anisms are an important subject of research. The principles of ADAM10 and -17 activity regula-
tions will be summarized in this chapter. 
 
1.3.1. Regulation of ADAM10 and ADAM17 protein expression, maturation and 
transport 
The regulation of transcriptional expression is poorly characterized despite the fact that AD-
AM10 and -17 expression is increased in several cancer types and associated with malignant 
cancer progression (Arribas et al., 2006; Borrell-Pagès et al., 2003; Ding et al., 2004; Gavert et 
al., 2005; Yoshimura et al., 2002). The expression of ADAM17 in endothelial cells can be up-
regulated by certain cytokines and growth factors (Bzowska et al., 2004). However, the mecha-
nisms remain poorly understood. In contrast to the transcriptional control, post-translational 
regulation is described for most ADAMs. The first step is the removal of the inhibitory prodo-
main by furin convertases, which occurs during the transit through the Golgi (Lum et al., 1998; 
Roghani et al., 1999). Inhibition of furin results in less ADAM17 substrate shedding and conse-
quently, overexpression of furin increases ADAM17 substrate shedding (Peiretti et al., 2003). 
Interestingly, Peiretti et al. also showed that pro-domain processing by furin is not a prerequisite 
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for ADAM17 surface expression. Nevertheless, prodomain processing is not a endogenously 
regulated step that controls the activity of ADAM17. More important than prodomain pro-
cessing is the transport and localization of ADAM17. Recent findings revealed that iRhom1 and 
-2, inactive members of the rhomboid protease family are required for ADAM17 maturation. In 
mice, iRhom2 is necessary to promote trafficking of ADAM17 in immune cells (Adrain et al., 
2012; Issuree et al., 2013; McIlwain et al., 2012). The other member of the murine iRhoms is 
iRhom1. It contributes to the maturation of ADAM17 in non-immune cells. A loss of either 
iRhom has a partially inhibitory effect, whereas double deficient cells have no ADAM17 activi-
ty (Christova et al., 2013). In iRhom2-deficient mouse embryonic fibroblast, stimulated shed-
ding of some substrates, such as HB-EGF and Kit-Ligand-2 is impaired, but shedding of other 
substrates seems to be normal (Maretzky et al., 2013).  
Protein binding partners are also known for ADAM10. Tetraspanins, a highly conserved trans-
membrane protein family, contribute to the maturation of ADAM10. It was shown that tetra-
spanin12 is able to regulate ADAM10-dependent amyloid precursor protein (APP) processing 
through enhanced maturation of ADAM10 (D. Xu et al., 2009). Additionally, tetraspanin15 
regulates trafficking and activity of ADAM10 by promoting the endoplasmic reticulum (ER) 
exit and stabilizing mature ADAM10 at the cell surface in mammalian cell lines (Prox et al., 
2012).  
Immunofluorescence studies suggest that the majority of ADAM17 is localized in perinuclear 
compartments and mature ADAM17 was found at the cell surface (Schlöndorff et al., 2000). 
Additionally, ADAM17 is packaged into lipid rafts during the transport through the Golgi and 
this spatial distribution contributes to the proteolytic function (Tellier et al., 2006).  
Taken together, protein-binding partners and lipid environments of ADAM10 and -17 are im-
portant for the maturation, transport and localization. Furthermore, these proteins and lipids may 
control the substrate selectivity and the proteolytic function of these proteases. 
 
1.3.2. The rapid activation of ADAM10- and -17-dependent shedding  
ADAM10 and -17 are constitutively active, but the shedding can rapidly be enhanced by several 
stimuli. These stimuli include some cytokines, G-protein coupled receptors (GPCR) -ligands, 
growth factors and unphysiological stimuli like phorbol esters, such as Phorbol-12-Myristat-13-
Acetat (PMA) and ionophores like ionomycin. These multifaceted activators of ADAM-
mediated shedding imply different signaling cascades, all leading to the rapid activation of 
ADAM17 and/or ADAM10 shedding, but the general underlying mechanism remains poorly 
characterized. Some important principles of these activating mechanisms will be outlined in this 
chapter. In general, three receptor classes transmit signals from the outside that can induce rapid 
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activation of ADAM10 and/or -17. These receptor classes are ligand-gated ion channels, g-
protein coupled receptors (GPCRs) and receptors with own or associated kinase activity. 
 
1.3.2.1 Ligand-gated ion channels 
Ligand-gated ion channels are membrane-spanning channels allowing ions like Na+, K+, Cl-, or 
Ca2+ to pass the membrane upon binding of a ligand. This receptor class consists of three super-
families, the cys-loop superfamily (nicotinic receptors, GABAA and GABAC receptors, glycine 
receptors, and some glutamate, histamine and serotonin activated anionic channels), the ATP-
gated ion channels (P2X1-P2X7) and the glutamate activated cationic ion channels (NMDA 
receptors, AMPA receptors, kainate receptors etc.).  
One example for ADAM activation through ligand-gated ion channels is the NMDA receptor. 
The N-methyl-D-aspartate (NMDA) receptor is a non-selective cation channel involved in syn-
aptic plasticity (Traynelis et al., 2010). Stimulation of this receptor, for example with glutamate, 
leads to an influx of Na+ and Ca2+ and an efflux of K+ and results in increased ADAM10-
dependent N-cadherin cleavage in neuronal cells (Reiss et al., 2005; Uemura et al., 2006). 
ADAM-mediated shedding can also be induced by another cation channel, the P2X7. The P2X7 
is a trimeric ATP-gated cation channel, which plays important roles in health and disease (Bart-
lett et al., 2014). Activation of this channel allows Na+, Ca2+ and K+ to pass the plasma mem-
brane leading to an increase in cytosolic calcium levels. This is followed by enhanced ADAM-
mediated shedding of CD23 and L-selectin in B- cells (Gu et al., 1998), of IL6-receptor in T-
cells (Garbers et al., 2011) and CXCL16 in peripheral B-lymphocytes (Pupovac et al., 2013) .  
 
1.3.2.2 G-protein coupled receptors 
G-protein coupled receptors are a large group of seven-transmembrane domain receptors with 
nearly 800 predicted human genes. They are involved in many physiological and pathophysio-
logical processes, such as homeostasis, inflammation, sensory perception and neuronal signal 
transmission and many more (Heng et al., 2013). GPCRs transduce extracellular signals to cou-
pled intracellular heterotrimeric G-proteins. Upon binding of the ligand and activation of the G-
protein the α-subunit dissociates from the β/γ subunits and each amplifies a second messenger 
response by activating or inhibiting various effector molecules. Four main classes of α-subunits 
are described (Gαs, Gαi/0, Gαq/11 and Gα12/13 (Gilman, 1987)), which activate distinct signaling 
events (reviewed in (Marinissen and Gutkind, 2001; Neves et al., 2002; Perez and Karnik, 
2005). ADAM-mediated shedding can be activated by several GPCR ligands. These ligands 
include inter alia lysophosphatidic acid (LPA), angiotensin II, thrombin, bradykinin, carbachol 
and acetylcholine. Stimulation of epithelial cells with these agents leads to a rapid activation of 
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ADAM-mediated shedding and transactivation of EGFR signaling by releasing EGFR ligands 
like HB-EGF and TGF-α (Prenzel et al., 1999; Schäfer et al., 2004). 
 
1.3.2.3 Receptors with own or associated kinase activity 
Receptors with their own kinase activity include the receptor tyrosine kinases (RTKs) like the 
EGFR, the vascular endothelial growth factor receptor 2 (VEGFR2) and the fibroblast growth 
factor receptor 2b (FGFR2b). RTKs promote migration and proliferation of cells (Iwashita and 
Kobayashi, 1992). The EGFR signaling and their consequences are depicted in chapter 1.2.3.  
One example for RTK-induced ADAM-mediated shedding is the VEGFR2. The VEGFR2 pro-
motes proliferation of endothelial cells by transactivating EGFR and ERK1/2 signaling via 
ADAM17-dependent release of EGFR-ligands (Maretzky et al., 2011a).  Another example is the 
keratinocyte specific FGFR2b, which promotes ADAM17-dependent EGFR activation in epi-
thelial cells (Maretzky et al., 2011a).  
Furthermore, Toll-like receptors (TLRs) are also involved in ADAM activation. They belong to 
the pattern recognition receptors, responsible for recognizing pathogenic molecules like lipo-
polysaccharides (LPS).  Stimulation of TLRs triggers the innate immunity by activating NFκB 
and other effector molecules (reviewed in (Akira and K. Takeda, 2004)). Additionally, activa-
tion of TLRs through LPS increases ADAM10 and -17-mediated “T cell immunoglobulin and 
mucin domain 3” (TIM-3) shedding in monocytes (Möller-Hackbarth et al., 2013). In LPS-
induced acute pulmonary inflammation alveolar recruitment of neutrophil and monocyte is re-
duced in mice lacking ADAM10 in hematopoietic cells (Pruessmeyer et al., 2014). These find-
ings indicate important roles for ADAM10 and -17 in TLR-induced innate immunity response, 
but the mechanisms involved remain unexplored. 
 
1.3.2.4 Intracellular signaling involved in ADAM regulation 
Various receptor ligands induce rapid activation of ADAM10 and -17 shedding by multifaceted 
intracellular signaling. No distinct signaling pathway is known that is responsible for the activa-
tion of ADAM10 or -17. Nevertheless, some general mechanisms are often associated with in-
creased ADAM10 and -17 proteolytic activity. This includes kinase activation and elevation of 
intracellular Ca2+ levels. 
Several kinases take part in the regulation of ADAM17 activity.  Most of them are able to phos-
phorylate ADAM17 at threonine 735 (T735). These kinases are protein kinase C (PKC) (Kil-
lock and Ivetić, 2010), protein kinase G (Chanthaphavong et al., 2012), src kinase (Maretzky et 
al., 2011b), phosphoinositide-dependent kinase 1 (PDK1) (Zhang et al., 2006), p38-mitogen-
activated protein kinase (p38-MAPK) (P. Xu and Derynck, 2010) and ERK (Rousseau et al., 
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2008). The phosphorylation of T735 increases the transport of ADAM17 to the surface (Soond 
et al., 2005) and prevents dimerization of ADAM17, which is a prerequisite for TIMP3 binding 
(P. Xu et al., 2012). TIMP3 is a physiological inhibitor of several metalloproteases including 
ADAM17 (Amour et al., 1998). Nevertheless, ADAM17 phosphorylation seems not to be the 
final activation step because rapid activation does not depend on TIMP3 removal and ADAM17 
lacking the cytotail can still be activated (Le Gall et al., 2010; Reddy et al., 2000).  
Another mechanism often associated with the rapid activation of ADAM-mediated shedding is 
elevation of intracellular Ca2+ (Horiuchi et al., 2007b; Le Gall et al., 2009).  Cytosolic calcium 
increase can occur either by extracellular Ca2+ influx, or by depletion of intracellular stores. The 
first is mediated by ion channels, like the ATP-gated channel P2X7 (Bartlett et al., 2014; 
Pupovac et al., 2013). The latter is often caused by Gq/11-coupled GPCR signaling, such as 
through thrombin activated PAR-1 (Hirano and Kanaide, 2003; Schulz et al., 2008).  
Phorbol esters and ionophores are the most used unphysiological stimuli of ADAM-mediated 
shedding. Whereas phorbol esters like PMA induce ADAM17 substrate shedding through PKC 
activation, ionophores like ionomycin activate ADAM10 and -17 substrates shedding via Ca2+ 
influx (Horiuchi et al., 2007b; Le Gall et al., 2009; Sahin et al., 2004). 
Taken together, the underlying mechanisms how kinases and/or Ca2+-levels contribute to the 
final activation of ADAM-mediated shedding remain unclear.  
 
1.3.3. Membrane dynamics as a regulatory mechanism for ADAM10 and -17 function 
All cells are surrounded by membranes, which define the border between intracellular and ex-
tracellular space. These membranes are composed of a lipid bilayer containing proteins that 
span the bilayer and/or interact with the lipids (Meer et al., 2008). Since ADAMs and their sub-
strates are transmembrane proteins embedded in this bilayer, it can be speculated that the lipid 
environment plays a role in the regulation of the shedding events. 5% of the eukaryotic genes 
encode for lipid synthases or lipid modifying proteins making up more than thousand different 
lipids (Sud et al., 2007). These vast numbers of lipids do not only contribute to barrier proper-
ties of membranes, they are also involved in energy storage, signaling events and interaction 
with proteins (Capelluto, 2013; Meer et al., 2008). The potential role of cell membranes, their 
lipid composition and their biophysical properties on ADAM-mediated shedding will be sum-




1.3.3.1 Membrane lipids: distribution and biophysical properties 
The major structural lipids in eukaryotic membranes are the amphiphilic glycerophospholipids 
phosphatidylcholine (PtdCho), phosphatidylethanolamine (PtdEtn), phosphatidylserine (PtdSer), 
phosphatidylinositol (PtdIns) and phosphatidic acid (PA) (Figure 5). 
 
Figure 5: Structures of the major lipids in eukaryotic membranes. Depicted are the structural formu-
las and the 3-D structures of the most abundant naturally occurring lipids L-α-phosphatidylcholine, 
L-α-phosphatidylserine, L-α-phosphatidic acid, L-α-phosphatidylethanolamine, cholesterol and 
L-α-phosphatidylinositol. (Pictures are taken from Avanti® Polar Lipids, Inc.). 
 
Their hydrophobic part consists of a diacylglycerol (DAG) and saturated or cis-unsaturated fatty 
acid chains of variable length. The hydrophilic part bears the characteristic head group. Togeth-
er, these parts of the lipid determine the molecular shape and the biophysical properties. The 
most abundant lipid is PtdCho (J. E. Vance and D. E. Vance, 2008). Most of them have one cis-







spontaneously build planar bilayers (J. E. Vance and D. E. Vance, 2008). Among the phospho-
lipids, several carry a negatively charged head group. These include the monoacidic phospholip-
ids like PtdSer and phosphadidylglycerol (PG) and the diacidic PA. Another, the PtdIns contains 
one negative charge, but can be conjugated with additional phosphate groups. These acidic 
phospholipids are often involved in ionic binding of proteins and will be discussed in more de-
tail in 1.3.3.3. 
Another class of structural lipids are sphingolipids. Their hydrophobic backbone consists of 
ceramide. The most abundant sphingolipids are sphingomyelin (SM) and glycosphingolipids 
(GSL). Most sphingolipids have saturated or trans-unsaturated fatty acyl chains, which provides 
them with the ability to aggregate more closely to each other in the membrane than phospholip-
ids. Another class of important structural lipids are sterols. In mammalian cells cholesterol is the 
predominant form. It contributes to the rigidity of membranes by modulating membrane fluidi-
ty. 
The different lipids and membrane proteins are not evenly distributed in a leaflet of the bilayer. 
Several findings suggest the participation of membrane proteins in organizing large functional 
complexes (Simons and Ikonen, 1997). Similar to proteins, lipids also tend to group together 
mediating lipid-lipid and lipid-protein interactions (J. E. Vance and D. E. Vance, 2008). To-
gether, this leads to a 2-dimensional patchiness of the cell membrane. Additionally, lipids of the 
plasma membrane display an asymmetric distribution between the two leaflets, with PtdSer and 
PtdEtn enriched in the cytosolic leaflet and SM and GSL in the non-cytosolic leaflet (Meer et 
al., 2008). This asymmetric distribution is accomplished either by insertion of the lipid in one 
leaflet and continual retention of the lipid in the leaflet, or by ATP-dependent flippases (P-type 
ATPases and ABC transporters) (Pomorski and Menon, 2006). The asymmetric distribution of 
lipids has important functional consequences. On the one hand, it allows proteins to interact 
with a lipid specifically at one site, on the other hand, the imbalance can contribute to mem-
brane bending, allowing vesicle budding (Pomorski and Menon, 2006). The distribution of li-
pids is highly regulated and changes can cause multiple effects. In apoptosis PtdSer translocates 
to the outer leaflet and serves as a signal for phagocytosis and propagates the blood coagulation 
(Devitt and Marshall, 2011; Lentz, 2003). The loss of lipid asymmetry could be caused by the 
action of lipid scramblases, which function in an ATP-independent manner to randomize lipids 
between the leaflets (Pomorski and Menon, 2006). Lipid scramblases are typically activated by 





1.3.3.2 The role of lipid rafts and membrane fluidity in ADAM regulation 
Certain lipids and proteins have the tendency to build lipid-lipid, lipid-protein and/or 
protein-protein interactions in the membrane. This leads to compartmentalization and special-
ized membrane areas which are involved in endocytosis, signaling and many other functions 
(Simons and Ikonen, 1997). These membrane areas have distinct lipid and protein composition 
due to phase separation of different lipids. One kind of specialized membrane areas are lipid 
rafts. Lipid rafts are defined as sphingolipid- and cholesterol-enriched ordered patches of specif-
ic proteins. Most of the lipids in rafts are thought to be enriched in saturated and longer fatty 
acids, what makes the rafts high ordered and less fluid (Simons and Sampaio, 2011).  
ADAM17 is incorporated in lipid rafts during the transport through the Golgi (Moreno-Càceres 
et al., 2014; Tellier et al., 2006). Consequently it was shown that disruption of lipid rafts 
through cholesterol depletion increases the ADAM-mediated shedding of several substrates. 
These substrates include among others CD30 (Tresckow et al., 2004), IL6R (Matthews et al., 
2003), TNF-α, TNFR1 and TNFR2 (Tellier et al., 2006). Although ADAM10 is not sequestered 
in lipid rafts, ADAM10-mediated substrate processing can also be rapidly activated by choles-
terol depletion (Kojro et al., 2001). That is shown inter alia for the ADAM10 substrates CD44 
(Murai et al., 2011), N-cadherin (Reiss et al., 2005), L1-CAM (Mechtersheimer et al., 2001) and 
APP (Kojro et al., 2001). ADAM-mediated shedding is also driven by membrane fluidity. Un-
saturated free fatty acids increase shedding of VE-cadherin and L-selectin of endothelial cells 
and leukocytes. This effect could be ascribed to increased fluidity of the plasma membrane and 
not to changes in ADAM enzymatic activity (Reiss et al., 2011).  
Taken together, the membrane environment and its biophysical properties play an important role 
in regulating ADAM function by localizing the proteases and their substrates in specific regions 
and by mobilizing or immobilizing ADAM10 and -17 in the membrane.  
 
1.3.3.3 Protein-Lipid Interactions 
The most apparent protein-lipid interaction is that of transmembrane proteins, which span the 
lipid bilayer (Contreras et al., 2011) The kind of interaction of a lipid with a transmembrane 
protein is defined by the relative residence time of a particular lipid at the protein-lipid interface 
(A. G. Lee, 2003). When a lipid shows a low affinity to a transmembrane domain (TMD), it is 
considered as a bulk lipid and shows a fast exchange rate with other lipids. Lipids that show a 
specific interaction with the transmembrane domain due to hydrophobic matching to the protein 
or by specific interactions with the polar head group are appointed as annular lipids. These an-
nular lipids surround the protein and build a shell (annulus) (Anderson and K. Jacobson, 2002). 
Lipids that are highly specific bound or integrated in transmembrane protein complexes are 
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considered as non-annular lipids. Although the TMD and the lipid environment seems to play a 
role for ADAM17-mediated shedding, no specific interactions with lipids are proven up to now 
(Le Gall et al., 2010; X. Li et al., 2007; Tellier et al., 2006).  
Another type of protein-lipid interactions are ionic interactions at the inner and outer layer of 
the membrane. Certain phospholipids are negatively charged (see 1.3.3.1) and can interact with 
proteins via polybasic residues (L. Li et al., 2014). These proteins include membrane proteins, 
soluble proteins and viral proteins. Some of these proteins have specific binding pockets like the 
pleckstrin homology (PH) domain from phospholipase C β1, which binds PtdIns(4,5)P2 (Razzi-
ni et al., 2000) or the C2 domain from Synaptotagmin-1, which binds PtdSer (Honigmann et al., 
2013). Synaptotagmin-1 is the main calcium sensor for neuronal exocytosis. It contains two 
Ca2+-binding domains (C2A and C2B). In that case Ca2+ acts as bridge for the binding of the 
negatively charged PtdSer to the binding pocket of synaptotagmin-1 and enables exocytosis 
(Honigmann et al., 2013). Proteins without specific binding pocket can ionically bind to phos-
pholipids through less structured polybasic sequences. Examples for these ionic protein-lipid 
binding are the src kinase (Buser et al., 1994; Sigal et al., 1994) and HIV-1 Nef (Gerlach et al., 
2009). The NH2-terminus of the src kinase contains a myristoylated glycin that can integrate 
into the plasma membrane and a polybasic motif in close proximity that binds to PtdSer (Buser 
et al., 1994; Murray et al., 1997; Sigal et al., 1994). The HIV-1 Nef has three membrane binding 
moieties which enable Nef to bind to the plasma membrane. Nef contains an N-terminal my-
roistoyl-modification, followed by a polybasic amino acid cluster and some aromatic residues. 
The membrane binding of Nef occurs in two steps: first by fast ionic protein-lipid interaction 
and insertion of the myroistoyl group, followed by slow insertion of the aromatic residues in the 
membrane (Gerlach et al., 2009). These protein-lipid interactions are often crucial for the proper 
functions of the proteins and determine the activity state of these proteins. One example is the 
T-cell receptor: binding of the ITAM region to the membrane and insertion of tyrosine side 
chains into the membrane prevents the spontaneous phosphorylation of the tyrosines. Upon 
activation an increase in local Ca2+ concentration and a decrease in local PtdSer disrupts this 
binding allowing tyrosine phosphorylation (Gagnon et al., 2012; Shi et al., 2013).  
 
1.3.3.4 Membrane disturbing peptides 
Bacterial pore forming toxins (PFTs) and antimicrobial peptides (AMPs) have the ability to 
perturb the plasma membrane by insertion. Whereas PFTs are secreted by bacteria and serve as 
virulence factors, antimicrobial peptides are part of the innate immune system and are released 
after TLRs and NLRs (Nod like receptors) activation.  
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The first hint that membrane-disturbing peptides can modulate ADAM function was published 
in 1996. Cells exposed to streptococcus pyogenes streptolysin-O (SLO) or to E. coli HlyA 
showed increased shedding of the ADAM substrates CD14 and IL-6R (Walev et al., 1996). This 
response is probably linked to P2X receptor activation because Skals et al. could show that the 
hemolysis properties of HlyA are accelerated by P2X channel opening in response to initial 
ATP release through the HlyA pore (Skals et al., 2009). 
Another example is the human antimicrobial peptide LL-37. It is stored in specific granula in 
immune and epithelial cells and is released in pathogenic infections. It permeates microbial 
membranes by building transmembrane pores (C.-C. Lee et al., 2011). Beside this primary tar-
get, LL-37 can act on eukaryotic cells. It induces fibroblast growth in a P2X7 dependent manner 
and activates the innate immune response at the airway epithelial surface by transactivating the 
EGFR (Tjabringa et al., 2003; Tomasinsig et al., 2008). In keratinocytes LL-37 contributes to 
wound healing by provoking migration of the cells via transactivation of the EGFR receptor 
(Tokumaru et al., 2005). These findings indicate the involvement of ADAM-mediated shedding 
in the LL-37 provoked physiological effects. Although not proven, a possible mechanism is that 
LL-37 activates P2X receptors direct or indirect, which in turn activates ADAM-mediated shed-
ding and transactivation of the EGFR. 
The serine protease inhibitor kazal type 9 (SPINK9) has structural similarities to AMPs. Recent-
ly Sperrhacke et al. could show that SPINK9 operates in a comparable way as LL-37. In 
keratinocytes it promotes wound healing by transactivation of the EGFR in a P2-receptor- and 
ADAM-dependent manner (Sperrhacke et al., 2014). 
Another AMP-related peptide is the bee venom component melittin (Lavialle et al., 1980). Bee 
venom consists of several bioactive peptides including apamin, adolapin, mast cell-
degranulating peptide and melittin. In this complex venom, melittin is the greates part, constitut-
ing 50% of the whole venom (Raghuraman and Chattopadhyay, 2007). Melittin is a amphipathic 
peptide of 26 residues and contains a hydrophobic stretch of 19 amino acids followed by a clus-
ter of four positively charged residues at the C-terminus (RSCB protein databank number 
2MLT). Melittin has several bioactive functions. For example, it is able to integrate into cell 
membranes causing membrane perturbations (Dawson et al., 1978; Lavialle et al., 1980; Schoch 
and Sargent, 1980; Sessa et al., 1969). Melittin is also been discussed as anti-cancer drug and 
substitute for conventional antibiotics (Duclohier, 2010; Oršolić, 2012). Several cancer cells can 
be selectively destroyed by melittin in vitro (Son et al., 2007). Additionally, its potential as an 
anti-cancer drug has been tested in animal models for hepatocellular carcinoma, breast cancer 
and prostate cancer, with positive outcome (Liu et al., 2008; Russell et al., 2004; Soman et al., 
2009). Furthermore melittin is ascribed as anti-inflammatory, anti-arthritic and pain-killing sub-
stance (Son et al., 2007). The underlying mode of action of melittin remains largely unknown. 
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Beside the membrane interaction melittin is able to activate phospholipase A2 (PLA2) and it 
promotes arachidonic acid synthesis (Vernon and Bell, 1992). The activation of PLA2 and acti-
vation of caspase-3 are reported to contribute to the anti-cancer effects of melittin (D.-O. Moon 
et al., 2006). If melittin influences ADAM-mediated shedding is unknown. One part of this the-
sis deals with investigations if and when how melittin affects ADAM-mediated functions. 
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2. Aim of this thesis 
The diverse and crucial effects of ADAM-mediated shedding in many physiological and patho-
physiological situations are subjects of intense research. ADAM proteases participate e.g. in 
cancer progression, inflammation and tissue homeostasis. A better understanding of the regulat-
ing mechanisms, which control ADAM functions would expand the knowledge about patho-
physiological conditions and may lead to new pharmacological targets. Many signaling events 
can drive ADAM activation. These include kinase activation and calcium elevation. The result-
ing cleavage of the ADAM substrates occurs outside of the cells in short proximity to the cell 
membrane. ADAM10 and ADAM17 lacking their cytotail can still be activated. This leads to 
the conclusion that the final signaling step, which transforms the signal from the inside to the 
outside, is independent of the intracellular part of the ADAMs. Since membrane composition 
and membrane dynamics affect ADAM activity and function, the hypothesis arises that the 
membrane plays a role as ultimate trigger for shedding and may also be involved in the trans-
formation of the activation signal from the inside to the outside of the cells. The aim of this 
thesis consists of two parts. The first part deals with the effect of the bee venom component 
melittin on ADAM function. Melittin is a membrane disturbing peptide with anti-microbial, 
anti-inflammatory and anti-cancer properties. In this context ADAMs release pro-inflammatory 
cytokines as well as EGFR ligands and may promote inflammation and cancer progression. 
How melittin affects ADAM-mediated shedding is unknown and this question is investigated in 
the first section of this thesis.  
In the second part, the role and function of membrane lipids, in particular phosphatidylserine, in 
determining ADAM activity is analyzed. The dynamic distribution of membrane lipids, as well 
as their properties to interact with and regulate proteins became more and more apparent in  
recent years. A prime candidate for inside-out signaling is PtdSer. PtdSer, normally localized in 
the inner leaflet of the cell membrane, can rapidly be exposed to the outside. A process original-
ly described for apoptosis, in which the permanent exposition affects the whole membrane. Re-
cent reports link the PtdSer exposure also to other cell functions and highlight that this exposure 
can be transient. The potential role of the membrane dynamic and PtdSer exposure on ADAM 
activity is investigated in the second section of this thesis. 
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3. Material and Methods 
3.1. Equipment and consumables 
Table 4: Consumables 
Consumable	   Provider	  
96-­‐well	  plates,	  flat	  bottom	   Sarstedt	  AG	  &	  Co,	  GER	  
Cell	  culture	  dishes,	  10	  cm	   Sarstedt	  AG	  &	  Co.,	  GER	  
Cell	  culture	  flask,	  75	  cm2	   Sarstedt	  AG	  &	  Co.,	  GER	  
Cell	  culture	  plates,	  12-­‐,	  24-­‐,	  96-­‐well	   Sarstedt	  AG	  &	  Co.,	  GER	  
Cell	  scraper,	  16	  cm,	  25	  cm	   Sarstedt	  AG	  &	  Co.,	  GER	  
Cover	  slips	   Menzel-­‐Gläser	  GmbH,	  GER	  
Falcon	  centrifuge	  tubes	   Sarstedt	  AG	  &	  Co.,	  GER	  
Glass	  flasks,	  1000	  ml,	  300	  ml	   Schott	  AG,	  GER	  
Imaging	   Dishes	   with	   glass	   bottom	   CG	  
(175	  µm),	  surface	  treated	  
PAA	  (GE	  Healthcare),	  USA	  
Microscope	  slides	   Menzel-­‐Gläser	  GmbH,	  GER	  
Microtubes	  with	  thread	   Sarstedt	  AG	  &	  Co.,	  GER	  
Neubauer	  chamber	   Brand	  GmbH	  &	  Co.	  KG,	  GER	  
Nitrogen	  tank	   AIR	  LIQUIDE	  Deutschland	  GmbH,	  GER	  
Parafilm	   American	  National	  Can	  Company,	  USA	  
Pasteur	  pipettes	   Carl	  Roth	  GmbH	  &	  Co.	  KG	  
Petri	  dishes	   Sarstedt	  AG	  &	  Co.,	  GER	  
Plastic	  box,	  airtight	   EMSA	  GmbH,	  GER	  
PVDF	  membrane,	  0.45	  µm	   Carl	  Roth	  GmbH	  &	  Co.	  KG	  
Serological	  pipettes,	  5	  ml,	  10	  ml,	  25	  ml	   Sarstedt	  AG	  &	  Co.,	  GER	  
Syringe	  filter,	  0.45	  µm	  pore	  size	   Sarstedt	  AG	  &	  Co.,	  GER	  
Whatman	  paper,	  1.5	  mm	   Carl	  Roth	  GmbH	  &	  Co.	  KG	  
 
Table 5: Standard equipment 
Equipment	   Manufacturer	  
-­‐80°C	  Freezer	  Forma	  900	  Series	   Thermo	  Scientific,	  USA	  
Analytical	  balance	   Kern	  &	  Sohn	  GmbH,	  GER	  
Analytical	  balance	   Denver	  Instruments,	  USA	  
Biophotometer	   Eppendorf,	  GER	  
Centrifuge	  5417R,	  fixed	  angle	  rotor	  F45-­‐30-­‐11	   Eppendorf,	  GER	  
Centrifuge	  5424,	  fixed	  angle	  rotor	  FA45-­‐24-­‐11	   Eppendorf,	  GER	  
Centrifuge	  5804R	  fixed	  angle	  rotor	  F34-­‐6-­‐38	   Eppendorf,	  GER	  
Centrifuge	  5810R,	  swing-­‐out	  rotor	  A-­‐4-­‐62	   Eppendorf,	  GER	  
Centrifuge	  Heraeus	  Multifuge	  X3R,	  fixed	  angle	  
rotor	  F14-­‐6x250LE	  
Thermo	  Scientific,	  USA	  
Chemiluminescence	  detector	  Fusion	  FX7	   Peqlab,	  GER	  
Digital	   camera	   EOS	   1100D	   with	   microscope	   Canon,	  JPN	  
Material and Methods  
22	  
adapter	  
Exhaust	  pump,	  BVC	  professional	   Vacuubrand,	  GER	  
Freezing	  container,	  Nalgene	  Mr.	  Frosty	   Thermo	  Fisher	  Scientific	  Inc.,	  USA	  
Heating	  block	   Eppendorf,	  GER	  
Heating	  cabinet	   Memmert,	  GER	  
Incubator	  Hera	  cell	  150	   Thermo	  Scientific,	  USA	  
Light	  microscope,	  invers	   Hund,	  GER	  
Magnetic	  stirrer	  CB162	   Stuart,	  USA	  
Microwve	  oven	   Samsung,	  GER	  
NanoDrop	  1000	  spectrophotometer	   Peqlab,	  GER	  
PH-­‐meter	  pH211	   HANNA	  Instruments	  GmbH,	  GER	  
Plate	  Reader	  EL800	   Biotek	  Instruments	  GmbH,	  GER	  
Plate	  reader	  FLx800	   Biotek	  Instruments	  GmbH,	  GER	  
Power	  Supply	  EV231	   Peqlab,	  GER	  
Power	  Supply	  PAC300	   Bio-­‐Rad	  Laboratories,	  Inc.,	  GER	  
Roller	  mixer,	  Stuart	  SRT6	   Bibby	  Scientific	  Ltd.,	  UK	  
Semi	  dry	  electroblotter,	  PerfectBlue	   Peqlab,	  GER	  
Shaking	  incubator	  Minitron	   Infors	  HT,	  GER	  
Single	  channel	  pipettes	   Abimed	  GmbH,	  GER	  
Sonificator	  	   Bandelin	  electronic	  GmbH,	  GER	  
Sterile	  work	  bench	   Köttermann	  GmbH	  &	  Co.	  KG,	  GER	  
Tank	  electroblotter	  Web	  S	   Peqlab,	  GER	  
Thermocycler	  peqSTAR	  96	  universal	   Peqlab,	  GER	  
Tilting	  shaker	  Unitwist-­‐RT	   Uniequip,	  GER	  
Tube	  rotator	  MACSmix™	   Miltenyi	  Biotech,	  GER	  
Vortexer	  Vortex	  Genie	   IKA,	  GER	  
Water	  bath	  GFL1004	   GFL,	  GER	  
Water	  purification	  system,	  TKA	  GenPure	   TKA,	  GER	  
 
3.2. Chemicals 
Table 6: Chemicals and provider 
Chemical	   Provider	  
1,10-­‐Phenantrolin	   Roth,	  GER	  
1,2-­‐dioleoyl-­‐sn-­‐glycero-­‐3-­‐phospho-­‐L-­‐serine	  
(PtdSer)	  
Avanti	  Polar	  Lipids,	  USA	  
1,2-­‐dioleoyl-­‐sn-­‐glycero-­‐3-­‐phosphocholine	  
(PtdCho)	  
Avanti	  Polar	  Lipids,	  USA	  
ADAM	  peptide	  substrate	  (soluble)	   Enzo	  Life	  Sciences,	  USA	  
Adenosinetriphosphate	  (ATP)	   Sigma,	  GER	  
Agar	  Agar	   Roth,	  GER	  
Ammoniumperoxidisulfate	  (APS)	   Roth,	  GER	  
Ampicillin	   Roth,	  GER	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AnnexinV-­‐FITC	   Sigma,	  GER	  
Apyrase	  from	  potato	   Sigma,	  GER	  
Bapta-­‐AM	   Tocris	  Bioscience,	  UK	  
BCIP®	  /NBT,	  Sigma	  Fast™	   Sigma,	  GER	  
Benzoylbenzoyl-­‐ATP	  (bz-­‐ATP)	   Sigma,	  GER	  
Bovine	  serum	  albumin	  (BSA)	   Sigma,	  GER	  
Bradford	  Coomassie	  Plus	   Fermentas,	  USA	  
Calciumchloride	  (CaCl2)	   Roth,	  GER	  
Cetuximab	  C225	   Merck,	  GER	  
Collagen	  from	  rat	  tail	   Roche,	  GER	  
Di-­‐sodiumphosphate	  (NH2POH4)	   Roth,	  GER	  
DIDS	  (4,4'-­‐Diisothiocyanatostilbene-­‐2,2'-­‐
disulfonic	  acid	  disodium	  salt)	  
Invitrogen,	  USA	  
Dimethylsulfoxid	  (DMSO)	   Roth,	  GER	  
Dulbecco´s	  Modified	   Eagle	  Medium	   (DMEM),	  
High	  Glucose	  (4.5	  g/l)	  
GE	  Healthcare,	  USA	  
ECL	  Advanced	   GE	  Healthcare,	  USA	  
Epithelial	   growth	   factor	   (EGF),	   recombinant	  
human	  
Immunotools,	  GER	  
Ethanol	  96	  %	  (EtOH)	   Roth,	  GER	  
Ethanolamine	   Sigma,	  GER	  
Ethylene	  glycol	  tetraacetic	  acid	  (EGTA)	   Roth,	  GER	  
Ethylenediaminetetraacetic	  acid	  (EDTA)	   Roth,	  GER	  
Evans	  blue	   Tocris	  Bioscience,	  UK	  
Fetal	  calf	  serum	  (FCS)	   GE	  Healthcare	  
Fibroblast	   growth	   factor	   7	   (FGF7),	   recombi-­‐
nant	  human	  
Immunotools,	  GER	  
GI254023X	  (GI)	   GlaxoSmithKline,	  UK	  
Glucose	   Roth,	  GER	  
Glycerin	   Roth,	  GER	  
Glycine	  	   Roth,	  GER	  
Gö6976	   Sigma,	  GER	  
GW280264X	  (GW)	   GlaxoSmithKline,	  UK	  
Hexokinase	  from	  saccharomyces	  cerevisiae	   Sigma,	  GER	  
Hydrochloric	  acid	  (HCl)	   Roth,	  GER	  
Hydroxyurea	   Sigma,	  GER	  
Ionomycin	  (IO)	   Calbiochem,	  GER	  
Isopropanol	   Roth,	  GER	  
L-­‐α-­‐phosphatidylcholine	   (PtdCho,	   Egg,	   Chick-­‐
en)	  
Avanti	  Polar	  Lipids,	  USA	  
L-­‐α-­‐phosphatidylserine	   (PtdSer,	   Brain,	   Por-­‐
cine)	  
Avanti	  Polar	  Lipids,	  USA	  
LSM	  1077	   	  
Magnesiumchloride	  (MgCl2)	   Merck,	  GER	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Magnesiumsulfate	  (MgSO4)	   Merck,	  GER	  
Marimastat	  (MM)	   Tocris	  Bioscience,	  UK	  
Melittin	   Produced	  by	  J.	  Andrä	  (FZ	  Borstel)	  
Mercaptoethanol	   Roth,	  GER	  
Methanol	  (MeOH)	   Roth,	  GER	  




O-­‐phospho-­‐l-­‐serine	  (OPLS)	   Sigma,	  GER	  
p-­‐Nitrophenyl	  phosphate	  (pNPP)	  tablets	   Sigma,	  GER	  
Penicillin/Streptomycin	  (100x)	   GE	  Healthcare	  
Phorbol-­‐12-­‐myristat-­‐13-­‐acetat	  (PMA)	   Sigma,	  GER	  
Phosphatase-­‐inhibitor	  mix	  (PhosStop)	   Roche,	  GER	  
Phosphocholin	  (PC)	   Sigma,	  GER	  
Potassiumchloride	  (KCl)	   Merck,	  GER	  
Potassiumdihydrogenphosphate	  (KH2PO4)	   Roth,	  GER	  
PP2	   Calbiochem	  GER	  
PP2	   Calbiochem,	  GER	  
PPADS	   Sigma,	  GER	  
Propidium	  iodide	   Sigma,	  GER	  
Protease-­‐inhibitor	  mix	  Complete	   Roche,	  GER	  
Proteinmarker	  PageRuler™	   Thermo	  Scientific,	  USA	  
pSIVA™-­‐IANBD	   Imgenex	  Corp.,	  USA	  
Saccharose	   Roth,	  GER	  
SITS	   (4-­‐Acetamido-­‐4ʹ′-­‐isothiocyanato-­‐2,2ʹ′-­‐
stilbenedisulfonic	  acid	  disodium	  salt	  hydrate) Sigma,	  GER	  
Sodiumchloride	  (NaCl)	   Roth,	  GER	  
Sodiumdodecylsulfate	  (SDS)	   Roth,	  GER	  
Staurosporine	  from	  streptomyces	  sp.	   Sigma,	  GER	  
Suramin	   Sigma,	  GER	  
TAPI-­‐0	   Sigma,	  GER	  
Tetramethylethylendiamin	  (TEMED)	   Roth,	  GER	  
Transfectionreagent	  Turbofect	   Thermo	  Scientific,	  USA	  
Tris	   Roth,	  GER	  
Triton	  X-­‐100	   Roth,	  GER	  
Trypsin-­‐EDTA	   GE	  Healthcare	  
Trypton/Pepton	  from	  casein	   Roth,	  GER	  
Tween®20	   Roth,	  GER	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3.3. Kits & ELISAs 
All Kits and enzyme linked immunosorbent assays (ELISAs) were performed according to 
manufacturer´s instructions. 
 
Table 7: Commercial kits and enzyme linked immunosorbent assays. 
Kit	   Provider	  
CellTiter	  Glo©	  Luminescence	  Cell	  Viabilty	  Assay	   Promega,	  USA	  
PureYield™	  MidiPrep	  Kit	   Promega,	  USA	  
PureYield™	  Midiprep-­‐Kit	   Promega,	  USA	  
QuickChange®	  II	  Site-­‐directed	  Mutagenesis	   Stratagene,	  USA	  
sTNFR1/TNFRSF1A	  ELISA	  DuoSet	  (human)	   R&D	  Systems,	  USA	  
TGF-­‐α	  ELISA	  DuoSet	  (human)	   R&D	  Systems,	  USA	  
 
3.4. Software 
Table 8: Software used for this thesis 
Software	   Developer	  
Adobe	  CC	  2014	   (Photoshop,	   Illustrator,	   InDe-­‐
sign,	  AcrobatPro,	  Media	  Encoder)	  
Adobe	  Systems,	  USA	  
AxioVision	   Zeiss,	  GER	  
Bio	  1D	   Vilber	  Lourmat,	  GER	  
Clone	  Manager	  9	   Scientific	  &	  Educational	  Software,	  USA	  
FluoView	  FV10-­‐ASW	  4	   Olympus	  corporation,	  JPN	  
Fusion	  15.17	   Vilber	  Lourmat,	  GER	  
GraphPad	  Prism	  5	   GraphPad	  Software	  Inc.,	  USA	  	  
ImageJ	  1.47m	   NIH,	  USA	  
Microsoft	  Office	  2011	   Microsoft	  Corp.,	  USA	  
Papers	  3	   Mekentosj	  B.V.,	  Netherlands	  
QuickChange®	  Primer	  Design	  
(http://stratagene.com/qcprimerdesign)	  
Stratagene,	  USA	  
UCSF	  Chimera	  1.1	   University	  of	  California,	  USA	  
3.5. Stimulants and inhibitors 
Table 9: Stimulants and inhibitors used for this thesis 
Name	   Utilization	   Concentration*	  
Apyrase	   ATPase	   2	  U/ml	  
Bapta-­‐AM	   Ca2+-­‐chelator	  (membrane	  permeable)	   50	  µM	  
bz-­‐ATP	   P2X7	  agonist	   300	  µM	  
Cetuximab	   EGFR-­‐blocking	  antibody	   10	  µg/ml	  
DIDS	   Inhibition	  of	  PtdSer	  exposure	   100	  µM	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EGF	   EGFR-­‐ligand	   4	  nM	  
EGTA	   Ca2+-­‐chelator	  (membrane	  impermeable)	   3	  mM	  
Evans	  blue	   P2-­‐receptor	  inhibitor	   1	  µM	  
FGF7	  (fibroblast	  growth	  factor	  
7)	  
FGFR2b-­‐ligand	   20	  ng/ml	  
GI254023X	  (GI)	   Preferential	  ADAM10	  inhibitor	   3	  µM	  
GW280264X	  (GW)	   Preferential	  ADAM10	  and	  -­‐17	  inhibitor	   3	  µM	  
Hexokinase	   ATP-­‐Hydrolase	   2	  U/ml	  
Hydroxyurea	   Inhibition	  of	  proliferation	   2	  mM	  
Ionomycin	  (IO)	   Ca2+-­‐ionophor	   1	  µM	  
Marimastat	   General	  metalloprotease-­‐inhibitor	   10	  µM	  
Melittin	   Bee	  venom	  component	   1	  µM	  
OPLS	   Competition	  for	  PtdSer	  binding	   10	  mM	  
PC	   Control	  for	  OPLS	   10	  mM	  
PMA	   PKC-­‐activator	   200	  ng/ml	  
PP2	   Src-­‐kinase-­‐inhibitor	   10	  µM	  
PPADS	   P2(X)-­‐receptor	  inhibitor	   100	  µM	  
SITS	   Inhibition	  of	  PtdSer	  exposure	   500	  µM	  
Staurosporine	   PKC-­‐inhibitor	   1	  µM	  
Suramin	   P2-­‐receptor	  inhibitor	   50	  µM	  
*Unless indicated otherwise 
 
3.6. Antibodies 
Table 10: Primary antibodies 
Antigen	   Reactivity*	   Provider	   Species	   Used	  dilution	  (WB)	  
E-­‐cadherin	   h	   BD	  Bioscience	   Mouse	   1:2500	  
EGFR	   h	   Cell	  signaling	   Rabbit	   1:3000	  
ERK1/2	   h	   Cell	  signaling	   Mouse	   1:3000	  
GAPDH	   h,	  m	   Santa	  Cruz	   Rabbit	   1:500	  
N-­‐cadherin	   h,	  m	   BD	  Bioscience	   Mouse	   1:2500	  
Phospho-­‐EGFR	   h	   Cell	  signaling	   Rabbit	   1:3000	  
Phospho-­‐ERK1/2	   h	   Cell	  signaling	   Rabbit	   1:3000	  
VE-­‐cadherin	   h	   Santa	  Cruz	   Mouse	   1:1000	  
*Reactivity: h: human; m: mouse 
 
Table 11: Secondary antibodies 
Name	   Coupling	   Provider	   Used	  dilution	  (WB)	  
Goat-­‐α-­‐mouse	  IgG	   POD	   Jackson	  ImmunoResearch	   1:10000	  
Goat-­‐α-­‐rabbit	  IgG	   POD	   Jackson	  ImmunoResearch	   1:10000	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3.7. Plasmids 
Table 12: Plasmids 
Name	   Vector	   Provider	  
ADAM17-­‐3X	   pcDNA3.1	  (Invitrogen)	   Mutated	  ADAM17-­‐WT	  
ADAM17-­‐E/A	   pcDNA3.1	  (Invitrogen)	   C.	  Blobel	  (HSS,	  New	  York)	  
ADAM17-­‐WT	   pcDNA3.1	  (Invitrogen)	   C.	  Blobel	  (HSS,	  New	  York)	  
P2X7	   pcDNA3.1	  (Invitrogen)	   C.	  Blobel	  (HSS,	  New	  York)	  
TGFα-­‐AP	   pAPtag5	  (GenHunter)	   C.	  Blobel	  (HSS,	  New	  York)	  
 
3.8. General buffer recipes 
Table 13: General buffer recipes. 
6x	  SDS	  sample	  buffer	   0.75	  M	  Tris	  
12	  %	  SDS	  
6.54	  M	  Glycerin	  
6	  mM	  EDTA	  
120	  mM	  DTT	  
0.15	  %	  Bromphenole	  blue	  
pH	  6.8	  
Alkaline	  phosphatase	  (AP)	  buffer	   100	  mM	  NaCl	  
100	  mM	  Tris	  
20	  mM	  MgCl2	  
pH	  9.5	  
Annexin	  binding	  buffer	   10	  mM	  HEPES	  
140	  mM	  NaCl	  
2.5	  mM	  CaCl2	  
pH	  7.4	  
Cell	  lysis	  buffer	  for	  AP-­‐assays	   1	  mM	  EDTA	  
10	  mM	  1,10-­‐Phenantrolin*	  
2,5	  %	  (v/v)	  Triton-­‐X-­‐100	  in	  H2O	  
Cell	  lysis	  buffer	  for	  western	  blotting	   5	  mM	  Tris	  
1	  mM	  EGTA	  
250	  mM	  Saccharose	  
1	  %	  (v/v)	  Triton-­‐X-­‐100	  
10	  mM	  1,10-­‐Phenantrolin*	  
1	  x	  Complete	  protease	  inhibitor	  mix	  (Roche)*	  
1	  x	  PhosStop	  phosphatase	  inhibitor	  mix	  (Roche)*	  
Electrophoresis	  buffer	   25.1	  mM	  Tris	  
192	  mM	  Glycin	  
0.1	  %	  SDS	  
pH	  8.8	  
Erythrocyte	  lysis	  buffer	   M	  KHCO3	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0.15	  M	  NH4Cl	  
0.1	  mM	  EDTA	  
pH	  7.5	  
PBS	   137	  mM	  NaCl	  
2.7	  mM	  KCl	  
1.8	  mM	  KH2PO4	  
10.1	  mM	  Na2HPO4	  
Resolving	  gel	  buffer	   1.5	  M	  Tris	  
0.4	  %	  SDS	  
pH	  8.8	  
Stacking	  gel	  buffer	   0.5	  M	  Tris	  
0.4	  %	  SDS	  
pH	  6.8	  
Stripping	  buffer	  for	  PVDF	  membranes	   62.5	  mM	  Tris	  
20	  %	  (w/v)	  SDS	  
0.7	  %	  (v/v)	  2-­‐mercaptoethanol*	  
TBS	   20	  mM	  Tris	  
1.17	  M	  NaCl	  
10	  mM	  EDTA	  
TBST	   20	  mM	  Tris	  
1.17	  M	  NaCl	  
10	  mM	  EDTA	  
0.1%	  Tween-­‐20	  
Transfer	  buffer	  for	  western	  blotting	   192	  mM	  Glycin	  
25	  mM	  Tris	  
10	  %	  MeOH	  
pH	  8.5	  
*Before use freshly added 
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3.9. Cell culture 
3.9.1. Cell lines 
 
Table 14: Cell types used 
Cell	  line	   Type	   Growth	  Medium	  
ADAM10	   and/or	   -­‐17-­‐
deficient	  MEFs	  	  
Generated	   from	   knockout	   mice	  
(Biochemistry	  Kiel)	  
DMEM	  +	  10	  %	  FCS	  +	  Pen/Strep*	  
CHO-­‐K1	   Chinese	   hamster	   ovary	   cells,	   epi-­‐
thelial	  like	  
Hams	  F12	  +	  10	  %	  FCS	  +	  Pen/Strep*	  
Cos-­‐7	   SV40	   transformed	   cell	   line	   from	  
kidney	   of	   cercopithecus	   aethiops,	  
fibroblast	  cells	  
DMEM	  +	  10	  %	  FCS	  +	  Pen/Strep*	  
Granulocytes	   Primary	   human	   granulocytes	  
(freshly	  prepared	  from	  blood)	  
RPMI	  	  
HaCaT	   Human	   keratinocytes,	   immortal-­‐
ized	  
DMEM	  +	  10	  %	  FCS	  +	  Pen/Strep*	  
HEK293	   Human	   embryonic	   kidney	   cells,	  
epithelial	  
DMEM	  +	  10	  %	  FCS	  +	  Pen/Strep*	  
HUVEC	   Primary	   human	   umbilical	   vein	  
endothelial	  cells	  
EGM	  +	  Supplements**	  +	  Pen/Strep*	  
Monocytes	   Primary	  human	  monocytes	  (fresh-­‐
ly	  prepared	  from	  blood)	  
RPMI	  
Murine	   embryonic	  
fibroblasts	  (MEF)	  
Immortalized	  Fibroblasts	   DMEM	  +	  10	  %	  FCS	  +	  Pen/Strep*	  
PBMC	   Primery	   peripheral	   blood	   mono-­‐
nuclear	   cells	   (freshly	   prepared	  
from	  blood)	  
RPMI	  	  
PSA3	   CHO-­‐K1	  cell	  line	  lacking	  functional	  
PSS1	  
Hams	   F12	  +	  10	  %	  FCS	  +	  Pen/Strep*	  
+	  10	  µM	  ethanolamin	  	  
*  Penicillin/Streptomycin: 100 U/ml 
**Endothelial supplements: 2 % FCS; Endothelial cell growth mixture 0.4 %, EGF 0.1 ng/ml, 
FGF 1 ng/ml, heparin 90 µg/ml, hydrocortisone 1 µg/ml (all obtained from Promocell as mixture). 
 
3.9.2. Cultivation of eukaryotic cell lines 
All cells were cultured at 37° C at 5 % CO2 in a humidified atmosphere. All media and buffers 
were stored at 4° C and preheated to 37° C before use. 
The adhesion cells were grown in T75 cell culture flasks until they reached a confluency of 80 -
 90 %. At this stadium they were either passaged for further propagation or seeded in cell cul-
ture plates for experiments. For passaging and seeding, the cells were once washed with PBS 
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and afterwards for round about 5 min incubated with trypsin-EDTA until they detach. To stop 
the proteolytic activity of trypsin, serum-containing medium was added (5 ml). Subsequently 
the cells were split in a 1:3 ratio into new flasks or seeded in the appropriate density in 6-, 12-, 
24-, or 96-well plates. If needed the cells were counted before seeding to adjust the appropriate 
density (see 3.9.6). 
The used suspension cells were all primary human blood cells, which were fresh prepared for 
each experiment and not cultivated for longer periods.  
 
3.9.3. Preparation of blood cells 
Blood samples from healthy donors were immediately mixed with heparin to a final concentra-
tion of 1 U/ml to prevent blood clotting. To prepare granulocytes and monocytes, whole blood 
samples were diluted with sterile PBS in a 1:2 ratio. 25 ml of this mixture were overlaid on 
12.5 ml LSM 1077 in 50 ml falcon tubes. The tubes were transferred to a centrifuge and a densi-
ty gradient was established by centrifuging for 30 min at 300 xg (RT, without break). In this 
gradient the cells separate on the basis of their weight and size and different fractions can be 
seen by eye (Figure 6). The red pellet contains erythrocytes and granulocytes. Upon this, a layer 
with LSM and granulocytes and a small band with PBMCs follow. This PBMC layer contains 




Figure 6: Scheme of the blood cell distribution before and after density gradient centrifugation. 
25 ml blood mixture is layered on top of 12.5 ml LSM 1077 (left side). After centrifugation for 30 min at 
300 xg the blood cells are separated on the basis of their size and weight with erythrocyte and granulo-









Leukocyte preparation by density-gradient centrifugation
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To isolate monocytes from the PBMC fraction, the fraction was removed and three times 
washed through centrifugation (300 xg, RT) with PBS. Than the cells were diluted in RPMI 
medium and plated into cell culture plates and incubated for 2-3 h at 37° C and 5 % CO2 in a 
humidified atmosphere. After this timespan, monocytes were adhered to the plate bottom and 
the non-monocytes can be washed away. Subsequent the monocytes were used in experiments. 
To isolate granulocytes, the granulocytes-containing fractions were washed three times with 
PBS (300 xg, RT). Subsequent, the erythrocytes were removed by re-suspending the cell pellet 
in ice-cold erythrocyte lysis buffer for 2 min. Then the suspension was centrifuged for 5 min 
and the supernatant removed. This procedure was repeated until the cell pellet was apparently 
free of erythrocytes. Finally, the granulocytes were washed three times with PBS, resuspended 
in RPMI and used for experiments. 
 
3.9.4. Cryopreservation of eukaryotic cells 
For long time storage, eukaryotic cells were stored at -196° C in liquid nitrogen. Therefor 80-
90 % confluent cells are washed and trypsinised as described in 3.9.2. Then the cells were re-
suspended in 1 ml of the corresponding medium containing 20 % FCS and 10 % DMSO and 
transferred into a freezing container. The freezing container contains MeOH, which guarantees 
a slow cool down of the cells. To support the slow cool down, the cells were stored for the first 
24 h at -80° C before they were transferred into liquid nitrogen. 
 
3.9.5. Collagenisation of cell culture dishes 
Some cell types cannot grow on plastic surfaces. These kinds of cells need additional matrix 
compounds to which they can adhere. To these cells belong the primary endothelial cells HU-
VECs. To promote the adhesion and growth of HUVECs, cell culture flasks and plates were 
coated with collagen. Collagen from rat-tail was suspended in PBS containing 0.02 M HCl to a 
concentration of 2000 µg/ml and stored at 4° C. The flasks and plates were coated with collagen 
at a final concentration of 20 µg/ml in PBS for at least 30 min. Then the plates and flasks were 
washed three times with PBS and dried before seeding the cells. 
 
3.9.6. Cell counting 
If indicated, the cells were counted before seeding and performing the experiments. Therefore, 
the trypsinized cells were centrifuged for 5 min with 300 xg at room temperature. Afterwards 
the cell pellet was resuspended in the corresponding medium and 10 µl of the cell suspension 
was diluted in a 1:1 or 1:10 ration in PBS with trypan blue. The final trypan blue concentration 
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was 0.2 %. Trypan blue stains dead cells but is excluded from viable cells. The cell count of 
viable cells was determined by counting the cells in a Neubauer counting chamber. By counting 
the viable cells in all four squares of the chamber the cell concentration of the cell suspension 







∗ 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑  𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 ∗ 10! 
 
 
3.10. MTT-based cell viability assay 
Metabolic activity was determined in 96-well plates in triplicates by quantifying the reduction 
of MTT ((3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazodium bromide) to formazan. Adhe-
sion cells were grown to confluency and suspension cells were counted and 200.000 cells per 
well were used. The cells were incubated with the indicated amount of melittin in 100 µl serum 
free medium for 30 min. Untreated and 2.5 % Triton-X treated cells served as control. After-
wards medium was replaced by 100 µl of 0.5 mg/ml MTT in 10 % standard cell culture medium 
and 90 % PBS and incubated for 2 h at 37° C. Formed formazan crystals were dissolved by 
adding 100 µl of 10 % Triton-X in isopropanol. Extinction was measured at 590 nm and ab-
sorbance values were normalized to untreated and Triton-X treated controls.  
 
3.11. Determination of ATP-release 
The CellTiter-Glo® Luminescent Cell Viability Assay (Promega) was used to determine the 
release of soluble ATP. The assay was performed according to manufacturer´s instructions and 
slightly adapted to measure extracellular ATP. In brief, cells were grown to confluency and 
incubated in 100 µl serum free medium with the indicated amounts of melittin for 30 min. Af-
terwards the supernatant was removed and centrifuged to remove cell debris. 50 µl of the condi-
tioned supernatant was mixed in a 1:1 ratio with the luminescent substrate. After 10 min at room 
temperature the luminescence was determined in a plate reader with an integration time of 1 s 
per well. The obtained luminescence values were interpolated with the values of an ATP stand-
ard curve ranging from 0 nM to 4000 nM, which were done in parallel. 
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3.12. Stimulation, cell lysis and collection of supernatants 
For the shedding analyses by western blotting, AP-assays or ELISAs all cells were stimulated as 
follows. If not otherwise indicated, all cells were pre-incubated for 1 h in serum free medium 
before stimulation. Inhibitors were added 15 min before the stimulation started to ensure that all 
target molecules are blocked. For all stimulants and inhibitors the corresponding solvent con-
trols were used to exclude unspecific side effects. After the indicated stimulation period the 
medium was removed and centrifuged at 13.000 rcf at 4° C for 5 min to remove cell debris. The 
cleared supernatants were either immediately used for ELISA- or AP-assays or stored at -20° C 
for later analyses. Depending on the kind of assay, different cell lysis buffer were used (Table 
13). Cell lysis was always performed on ice or at 4° C in the fridge. For western blotting anal-
yses, the cells were directly lysed through adding 100-200 µl pre-chilled lysis buffer in the wells 
and freezing and thawing them for three times in a row. Afterwards the lysis solution was trans-
ferred into Eppendorf tubes and incubated for 30 min on ice. The lysed cell solution was cleared 
by centrifugation at 13.000 rcf at 4° C for 5 min. The supernatants, containing the proteins, were 
either directly used or stored at -20° C for later analyses. 
For AP-assays the cells were lysed by adding 200 µl lysis buffer to the wells and the plates were 
incubated for 30 min and slow shaking at 4° C. Afterwards the lysis solution was transferred to 
Eppendorf tubes and incubated for further 30 min on ice. Finally, the solution was cleared by 
centrifugation at 13.000 rcf at 4° C for 5 min. The cleared solution was than directly used for 
AP-assays.  
 
3.13. Bradford protein concentration determination 
To determine the protein concentration in lysed cell solutions the Bradford protein concentra-
tion assay was used (Bradford, 1976).  Therefor 200 µl of a ready-to-use Coomassie Plus solu-
tion was mixed with 1 µl of the cell lysate. 1 µl pure lysisbuffer served as control. The extinc-
tion was measured at 595 nm in a plate reader. The protein concentrations were calculated by 
interpolation with a BSA standard curve. 
3.14. SDS polyacrylamide gel electrophoresis 
The SDS polyacrylamide gel electrophoresis is a standard procedure to separate proteins ac-
cording to their size ranging from 5 to 2000 kDa due to the uniform pore size provided by the 
polyacrylamide gel. Therefor 50 µg proteins per sample were boiled up to 95° C in 1x SDS 
sample buffer for 5 min. The now denaturated proteins were loaded onto the gel as well as the 
protein size marker PageRuler™. The stacking gel had by default 4.5 % and the resolving gel 
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10 % polyacrylamide (Table 15). The electrophoresis was performed at 30 mA and a maximum 
of 150 V. 
 
Table 15: Composition of the SDS polyacrylamide gels 
Stacking	  Gel	  4.5	  %	   2.9	  ml	  H2O	  
1.25	  ml	  Stacking	  gel	  buffer	  
825	  µl	  Acrylamide/Bisacrylamide,	  30%,	  37.5:1	  
30	  µl	  APS	  10	  %	  (w/v)	  
15	  µl	  TEMED	  
Resolving	  Gel	  10	  %	   4.03	  ml	  H2O	  
2.5	  ml	  Resolving	  gel	  buffer	  
3.33	  ml	  Acrylamide/Bisacrylamide,	  30%,	  37.5:1	  
60	  µl	  APS	  10	  %	  (w/v)	  
30	  µl	  TEMED	  
 
3.15. Western blotting 
To transfer the electrophoretically resolved proteins from the gel to a polyvenylidene fluoride 
(PVDF) membrane either the semid-dry or the tank blotting procedure were used. The semi-dry 
blotting was used for subsequent detection of cadherins and the tank blotting for subsequent 
detection of phosphorylated and unphosphorylated EGFR and ERK1/2. In brief, for both proce-
dures the PVDF membrane was prepared by activating it in MeOH. The activated membrane 
and the gel were put between to Whatman paper with the membrane oriented to the anode and 
the gel at the side of the cathode. The transfer was performed at XX for XX for the semi-dry 
blotting and at 80 mA for 12 h for the tank blotting. 
3.16. Immunological detection of transferred proteins 
To block unspecific antibody binding the membrane was incubated for 1 h at room temperature 
in TBST with 5 % milk powder. Afterwards the membrane was incubated with the indicated 
antibody dilution (Table 10) in blocking solution for 1h at room temperature. Antibodies from 
Cell signaling were incubated overnight at 4° C. After the first antibody incubation, the mem-
brane was washed three times for 5-15 min with TBST to remove excessive antibody binding.  
A second antibody with reactivity against the species of the first antibody was than incubated 
for 1h in TBST (Table 11). Unbound antibody was again washed away three times for 5-15 min 
with TBST. The antibody tagged proteins were detected with the peroxidase substrate ECL Ad-
vanced and the emitted chemiluminescence was recorded with a CCD camera (Fusion FX7, 
Peqlab). 
Material and Methods 
35 
3.17. Stripping of PVDF membranes 
The removal of the first and secondary antibodies of the PVDF membrane allows detecting dif-
ferent targets with different antibodies by using the same membrane. This method is called 
“stripping”. In this thesis it was for example used to subsequently stain phosphorylated and 
unphosphorylated ERK1/2 as well as p-EGFR and EGFR. To strip the antibodies off the mem-
brane, the membrane was incubated for 15-45 min in stripping buffer at 65° C (Table 13). The 
further procedure was than analogue to chapter 3.16 
 
3.18. Enzyme-linked immunosorbent assay 
The enzyme linked immunosorbent assays used in this thesis were designed to detect soluble 
human TGF-α and TNFR1, respectively. Both are distributed by R&D Systems and were used 
according to the manufacturer´s instructions with a slight adaption. Instead of 100 µl sample 
and 100 µl antibody dilutions per well, 50 µl were used. 
 
3.19. Cell cycle analysis 
The cell cycle analysis was performed by Anja Fries (University Mainz). In brief, HaCaT 
keratinocytes were cultured overnight in medium containing FCS before starvation of 48 h. 
Subsequently, medium containing various agents was added and cells were incubated for 24 h. 
For FACS analyses, cells were trypsinized and fixed with 75% ethanol in PBS/EDTA for ≥ 12 h 
at 4°C. Samples were centrifuged and re-suspended in PBS with EDTA (1 mM), containing 10 
µg/ml RNase. Propidium iodide staining was performed at a final concentration of 2 µg/ml. 
 
3.20. In vitro wound healing assay 
HaCaT keratinocytes were seeded in 12-well plates and grown until they reached confluence. A 
cell free area was introduced by scraping the monolayer with a pipette tip (10 µl). To avoid a 
proliferative effect, the cells were treated with 2 mM hydroxyurea for 24 h. For stimulation 
experiments, serum free medium containing metalloprotease inhibitors or DMSO as solvent 
control were added. After 15 min of preincubation the cells were treated with 0.5 µM melittin. 
The cells were photographed before and 24 h after stimulation by using an inverted phase-
contrast microscope (Zeiss). The cell free area was quantified using AxioVision (Zeiss) before 
and after stimulation, respectively.  
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3.21. Transient transfection of eukaryotic cells 
The insertion of expression vectors into eukaryotic cells was done by lipofection. The transfec-
tion solution was prepared as follows. For single transfection 100 µl serum free medium was 
supplemented with 0.5 µg plasmid and subsequently 1 µl Turbofect in a small tube. The tube 
was inverted a few times and incubated at room temperature for 20 min. For double transfection 
0.5 µg of plasmid 1 and 0.5 µg plasmid 2 were added to 100 µl serum free medium and 1.5 µl 
Turbofect was added afterwards. The cells were transfected at 60-80 % confluence and the me-
dium was changed to 500 µl serum free medium. The transfection solutions described above 
were then added in drops to the cells. After 6 h the medium was changed to normal growth me-
dium including FCS. 24 h after transfection the cells were used for stimulation experiments, 
such as for AP-assays.  
 
3.22.  Phosphatidylserine deprivation with PSA3 cells 
PSA3 cells were cultivated in Hams F12 medium supplemented with 10 % FCS, 10 µM ethano-
lamine and penicillin/streptomycin (Pen/Strep). For phosphatidylserine (PS) deprivation, cells 
were cultured in starvation medium consisting of Hams F12 with 6 % dialyzed FCS + Pen/Strep 
with or without 10 µM ethanolamine. For AP-assay experiments, PSA3 cells were transfected 
after 72 h PS deprivation for 6 h in Hams F12 only. Thereafter medium was changed again to 
the starvation medium. All AP-assays and imaging experiments were done after 96 h of PS dep-
rivation as described.  
 
3.23. Shedding experiments with alkaline phosphatase coupled 
substrates 
The proteolytic activity of ADAM17 in its wildtype or mutated form was determined with alka-
line phosphatase (AP) tagged substrates. These substrates (e.g. TGF-α-AP) carry an alkaline 
phosphatase at their extracellular domain, which is released in the supernatant after ADAM17-
mediated cleavage. These substrates were transfected into eukaryotic cells as described in chap-
ter 3.21. The activity of the AP can be determined by the hydrolysis of the colorless substrate p-
nitrophenylphosphat (p-NPP) to the yellow p-nitrophenol (p-NP). The ratio between the AP-
activity in the supernatant to the AP-activity in the cell lysates is a direct measure for the rela-
tive quantity of shed ADAM17-substrates. 24 h after transfection the cells were stimulated, 
lysed and the supernatant collected as described (chapter 3.12).  
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3.24. Fluorescence microscopy 
3.24.1. Life cell imaging 
Time-lapse imaging was performed with an inverted confocal microscope (Fluoview FV1000, 
Olympus) equipped with an environmental chamber using a UPLSAPO 60x oil immersion ob-
jective and 2x zoom. Before starting the experiments the chamber was equilibrated to 37°C in a 
humidified atmosphere. The cells were seeded in glass bottom imaging dishes (PAA) and grown 
till semi-confluency. Cells were allowed to rest for at least 1h in the microscope stage. PSIVA-
IANBD (Imgenex) was added to the cells in a final concentration of 6.25 µg/ml 5 min before 
acquisition started. PSIVA-IANBD was excited at 488 nm and emission was recorded at 
520 nm every 30 s or 60 s. Laser and detector settings were the same for each single experi-
ment.  
 
3.24.2. AnnexinV staining of cells 
Cells were seeded on glass coverslip and grown until semi-confluence. After indicated stimula-
tion/inhibiton periods coverslips were immediately incubated with 1:20 solution of FITC-
AnnexinV (Sigma) in Annexin-Binding-Buffer (Table 13) for 5 min in the dark at room temper-
ature, washed twice with ABB and were fixed for 15 min with 3 % PFA. After fixation co-
verslips were washed six times with PBS, once with Aqua dest and mounted in embedding me-
dium. Image acquisition was performed with an inverted confocal microscope (Fluoview 
FV1000, Olympus) using a UPLSAPO 60x oil immersion objective and 2x zoom. FITC-
AnnexinV was excited at 488 nm and emission was recorded at 520 nm. All images were ac-
quired with the same laser and detection settings. 
 
3.24.3. Fluorescence quantification 
Image analysis was done with ImageJ 1.47m. Fluorescence area above background fluorescence 
was determined and correlated to the cell growth area. AnnexinV staining:  for each group, three 
independent coverslips, each with 6-8 images of different areas were analyzed. The mean fluo-
rescence area of each coverslip was taken for statistical analysis. Control and stimulated groups 
were compared with an unpaired, one-tailed t-test (*p<0.05). 
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3.25. Electrostatic surface modeling 
Computational modeling of electrostatic protein surfaces was used to obtain an impression of 
the ionic charge distribution in the membrane proximal domain of ADAM17. The structures 
(accession number: 2M2F) were prepared with the PDB2PQR tool of the UCSF chimera soft-
ware package using the CHARMM force field method and the electrostatic potential map was 
calculated with the Adaptive Poisson-Boltzmann Solver (APBS) (Baker et al., 2001; Dolinsky 
et al., 2007; 2004; MacKerell et al., 1998; Unni et al., 2011).  
 
3.26. Preparation of lipid aggregates/liposomes 
Liposomes were prepared as 1 mM aqueous dispersions of the phospholipids in buffer (5 mM 
Hepes, 100 mM KCl, pH 7.0) as follows. The lipids were dissolved in chloroform to a concen-
tration of 1 mg/mL. The solvent was evaporated under a stream of nitrogen, buffer was added, 
and sonicated with a Branson sonicator (Branson Ultrasonics Corporation, Danbury, USA) for 1 
min (1 mL solution). Subsequently, the preparation was cooled for 30 min at 4 °C and two times 
heated for 30 min at 60 °C and cooled to 4 °C. Preparations were stored at 4 °C overnight prior 
to measurements. 
 
3.27. Isothermal titration calorimetry and surface acoustic wave 
biosensor measurements 
The isothermal titration calorimetry (ITC) and the surface acoustic wave biosensor measure-
ments (SAW) were performed at the Department of Biophysics, Forschungszentrum Borstel. 
Lena Heinböckel and Christian Nehls carried out these experiments. In brief, the binding of the 
MPD with PtdCho or PtdSer liposomes was analysed by microcalorimetric measurements on an 
ITC200 (GE Healthcare, Munich, Germany). 0.5 mM solutions of the open and closed form of 
MPD in 5 mM HEPES were titrated 20 times in 1.5 µL injections to 250 µL 0.1 mM PtdSer or 
PtdCho liposome dispersions. Final lipid:protein ratio was 5:3 [M:M]. The enthalpy changes 
were recorded versus time. The heats of dilution were determined in control experiments by 
injecting peptide solution into buffer (5 mM HEPES, pH 7.4). Measurements were performed at 
37 °C. 
For the SAW measurements, gold-coated chips (S-sens K5 Biosensor Quartz Chips, SAW In-
struments GmbH, Bonn, Germany) were functionalized as described before (Andrä et al. 2008). 
A functionalized chip was incubated overnight in ethanol and placed into the reader unit of the 
S-sens K5 readout system (SAW Instruments GmbH, Bonn, Germany). Biomolecular interac-
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tion processes on the surface of the sensor chip can result in changes of phase and amplitude of 
the surface acoustic wave. Changes of these parameters correlate with mass loading and viscoe-
lastic alterations (Andrä et al. 2008). Measurements were performed at a continuous flow of 
measuring buffer (5 mM HEPES, pH 7.4) of 20 µL/min at 22 °C. By injection of 100 µL of 
poly- L-lysine (PLL, 50 µg/mL, Fluka, Basel, Switzerland) a positively charged layer was 
formed on top of the negatively charged CM-dextran matrix. 100 µl phospholipid liposomes 
(300 µg/ml) (PtdSer liposomes or PtdCho (9):PtdSer (1) liposomes) were injected and immobi-
lized on the positively ionized surface. The liposomes were dissolved in 150 mM NaCl, 5 mM 
HEPES, pH 7.4 to ensure a homogenous surface coverage. Subsequently, 100 µl of 20 µg/ml 
solutions of the open and closed form of MPD in 5 mM HEPES were injected. Changes of 
phase and amplitude induced by the interaction of MPD with the lipid bilayer were recorded 
versus time.  
 
3.28. Mutagenesis 
For mutagenesis the QuickChange® II Site-directed Mutagenesis kit (Stratagene) was used ac-
cording to the manufacturers’ instructions. Felix Kordowski (Institute of Dermatology and Al-
lergology, UKSH Kiel) carried out the mutagenesis primer design and reactions. 
 
3.28.1. Plasmid 
The pcDNA-ADAM17 plasmid that was used for the mutagenesis experiments consists of the 
pcDNA3.1 expression vector (Invitrogen) and a 2484 bp fragment, which encodes for the mu-
rine ADAM17. The coding sequence contains the whole length ADAM17 with the prodomain 
as well as a hemaglutinin (HA) tag. This HA-tag is C-terminal added to the cytoplasmic tail of 




The primer oligonucleotides that were used to introduce site directed mutagenesis in the 
pcDNA-ADAM17 expression plasmids were designed with the online tool QuickChange® Pri-
mer Design (http://stratagene.com/qcprimerdesign). The primers were then ordered from Sigma 
Aldrich. The sequences of the mutagenesis primer pair are depicted in Table 16. 
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Table 16: Mutagenesis primer pair for the mutation of ADAM17. 
A17	  3x	  forward	   5'-gcagagcaaaagaacttgtttttggggggaggggggccatgtacagtagggttttgcg-3' 
A17	  3x	  reverse	   5'-cgcaaaaccctactgtacatggcccccctccccccaaaaacaagttcttttgctctgc-3'	  
3.28.3. Mutagenesis reaction 
The mutagenesis reaction was carried out according to the manufacturers’ instructions. In brief, 
a polymerase chain reaction was performed with the PfuUltra HF DNA-polymerase in the pres-
ence of the pcDNA-ADAM17 expression plasmid and the mutagenesis primer pair. The during 
the PCR synthesized new plasmids carrying the mutation do not have bacterial methylated DNA 
and are therefor protected against the afterwards performed digestion with Dpn I endonuclease. 
The resulting plasmids were than amplified in E. coli XL1 blue (3.28.5), isolated (3.28.7) and 
sequenced (3.28.8). 
 
3.28.4. Preparation of chemical competent cells 
 
Table 17: Buffer and solutions for the preparation of chemical competent cells. 
LB	  medium	   171	  mM	  NaCl	  
10	  %	  (w/v)	  Trypton/Pepton	  
5	  %	  (w/v)	  Yeast	  extract	  
Tris	  buffer	   0.1	  mM	  NaCl	  
5	  mM	  Tris	  
5	  mM	  MgCl2	  
CaCl2-­‐solution	   0.1	  mM	  CaCl2	  
5	  mM	  Tris	  
5	  mM	  MgCl2	  
 
To obtain chemical competent E. coli cells, XL1 blue cells were treated with CaCl2. Therefore, 
bacteria from an overnight culture were diluted 1:100 with LB medium and cultivated at 37° C 
and 200 rpm until they reached a optical density (OD600) around 0.4-0.6. The cells were than 
cooled down for 20 min on ice and centrifuged afterwards (5 min, 5000 xg). A cell pellet of a 
50 ml suspension was re-suspended in 20 ml pre-chilled Tris-buffer and centrifuged again for 
10 min at 4° C for 10 min. Subsequently the cell pellet was re-suspended in 20 ml CaCl2 solu-
tion and incubated for 20 min on ice. After this incubation, the cells were centrifuged (10 min, 
5000 xg, 4° C) and re-suspended in 2 ml of the CaCl2 solution. Once again, the cells were incu-
bated on ice for 1 h and filled up with 500 µl glycerin. This cell suspension was immediately 
shock frosted in liquid N2 and stored in aliquots of 50 µl at -80° C. 
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3.28.5. Transformation of chemical competent bacteria 
 
Table 18: Medium and solutions for the transformation of bacteria 
SOC	  medium	   0.5	  %	  (w/v)	  Yeast	  extract	  
2.0	  %	  (w/v)	  Trypton	  
10	  mM	  NaCl	  
2.5	  mM	  KCl	  
10	  mM	  MgCl2	  
10	  mM	  MgSO4	  
20	  mM	  Glucose	  
LB/Amp	  plates	   171	  mM	  NaCl	  
1%	  (w/v)	  Trypton/Pepton	  
0.5	  %	  (w/v)	  Yeast	  extract	  
1.5	  %	  (w/v)	  Agar	  Agar	  
0.1	  mg/ml	  Ampicillin	  
 
For the transformation process of cells, 50 µl of the above-described chemical competent XL1 
blue were gently thawed on ice and mixed with 1 µl plasmid. This mixture was first incubated 
for 45 min on ice and then warmed up for exactly 40 s to 42° C. The cells were cooled down for 
5 min on ice and filled up with 300 µl SOC medium. This bacteria culture was than incubated 
for 1 h at 37° C at 200 rpm. Afterwards the cell suspension was plated onto LB/Amp plates and 
incubated overnight at 37° C. Colonies were picked with a sterile pipette tip and incubated in 
5 ml LB medium containing ampicillin. This preculture was grown to an OD600 of 0.5 and used 
for the preparation of glycerol stocks. 
 
3.28.6. Preparation of bacterial glycerol stocks 
For long time storage of transformed bacteria, glycerol stocks were prepared. For this, 850 µl of 
a bacteria culture were mixed with 150 µl glycerol. This suspension was shock frosted in liquid 
nitrogen and afterwards stored at -80° C.   
 
3.28.7. Isolation of plasmid DNA from E.coli 
To amplify and isolate plasmids from transformed bacteria, 250 µl LB medium containing am-
picillin was inoculated with bacteria from glycerol stocks. This bacteria culture was incubated 
overnight at 37° C and 200 rpm. The plasmids were isolated with the PureYield™ MidiPrep kit 
(Promega) according to the manufacturer´s instructions. 
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3.28.8. DNA sequencing 
The sequences of the mutated plasmids were verified by commercial DNA sequencing (Seqlab).  
Therefor, 650 ng plasmid DNA was mixed with 20 pmol of the sequencing primer Se-
qpcDNA3.1BGHrev (5´-CTAGAAGGCACAGTCGAG-3´) in a volume of 7 µl and send in to 
Seqlab. 
 
3.29. Cleavage experiments with a soluble fluorogenic ADAM 
substrate  
Cos7 cells were transfected in 24 well plates with 0.5 µg of the ADAM17-plasmids (wildtype, 
E/A or 3x), or with the empty control plasmid (pcDNA3.1) for 6 h. 24 h after transfection medi-
um was changed to DMEM only with 10 µM fluorogenic ADAM substrate (Enzo Life Scienc-
es) and the cells were incubated for 6 h at 37°C and 5 % CO2 in a humidified atmosphere. Af-





4.1. Melittin modulates keratinocyte function through P2-receptor-
dependent ADAM activation 
 
The first part of the results section deals with the influence of the bee venom component melit-
tin on ADAM-mediated shedding. These results have been published in the Journal of Biologi-
cal Chemistry in 2012 (see supplements (Sommer et al., 2012)). 
 
4.1.1. Melittin affects cellular viability 
Melittin is known to induce necrosis and apoptosis in high concentrations, while low concentra-
tions enhance cell migration (Maher and McClean, 2008). To exclude potential cytotoxic side 
effects and define sublethal concentrations, MTT reduction was measured and taken as parame-
ter for cell viability. Viable and metabolically active cells reduce the yellow tetrazolium MTT to 
purple formazan, what can be quantified. As shown in Figure 7 (A-E) all cells tested responded 
to melittin treatment with a dose-dependent decrease in MTT reduction.  
Human umbilical vein endothelial cells (HUVECs) and murine embryonic fibroblasts (MEFs) 
were least sensitive to melittin treatment (Figure 7 B-C). 4 µM and 2 µM melittin were suffi-
cient for significant lowering of MTT reduction in HUVECs and MEFs In contrast to these 
cells, human monocytes were most sensitive and were not used in the following experiments 
(Figure 7A). Concentrations of ≥ 0.5 µM melittin lead to a significant decrease in MTT reduc-
tion in monocytes. The MTT reduction in human neutrophil granulocytes and HaCaT keratino-
cytes were significantly decreased at ≥ 1 µM and ≥ 2 µM melittin respectively (Figure 7 D-E). 
These results were in line with the previously reported tolerable threshold of 1 µM melittin for 
HaCaT keratinocytes (Drechsler and Andrä, 2011). 
In conclusion, these results indicate that melittin concentrations between 0.5 µM and 1 µM were 
tolerable for most cell types. Thus, these concentrations were used for the following experi-
ments, except for MEFs where higher concentrations were needed to stimulate significant shed-
ding. 
To test whether melittin treatment lead to ATP release, ATP concentrations in the supernatant of 
HaCaT keratinocytes were measured (Figure 7 F). ATP concentrations were determined by 
luciferase bioluminescence measurements (CellTiter-Glo Luminescent Cell Viability Assay 
(Promega)). Melittin treatment elicited ATP-release dose-dependently. It became detectable in 





Figure 7: Low concentrations of melittin do not affect cell viability. Primary human monocytes (A), 
murine embryonic fibroblasts (MEFs) (B), human umbilical vein endothelial cells (HUVECs)  
(C), primary human granulocytes (D) and HaCaT keratinocytes (E, F) were incubated with different con-
centrations of melittin for 30 min. Thereafter, cells were incubated for 2 h with MTT allowing MTT re-
duction. MTT reduction was determined by absorbance measurements and taken as a parameter for via-
bility. Absorbance values of melittin treated cells were normalized to untreated (100 %) and 2.5 % Tri-
ton-X treated cells (0 %) (A-E). ATP release of melittin treated HaCaT keratinocytes was determined by a 
luminescence ATP-dependent luciferase based Assay. Luminescence values were interpolated with a 
ATP standard curve (F). Data represent mean values ± S.E. of three independent experiments all meas-
ured in triplicates. * Indicates significant difference compared to control (* p < 0.05, ** p < 0.01, 





4.1.2. Melittin induces ADAM-dependent substrate cleavage 
To elicit if melittin would stimulate ADAM10-dependent shedding, N-cadherin processing in 
MEFs was determined. Therefore a monoclonal antibody against the C-terminus of N-cadherin 
was used to visualize the C-terminal fragment (CTF) and the full length N-cadherin in im-
munoblots of melittin treated MEF cell lysates (Figure 8 A). The generation of N-cadherin CTF 
in wildtype cells was compared with ADAM10-deficient fibroblast. Melittin dose-dependently 
evoked shedding of N-cadherin in wildtype cells. ADAM10-deficient MEFs exhibited no N-
cadherin shedding.  
 
 
Figure 8: Melittin increases ADAM-mediated shedding in different cell types. A: MEFs were mock 
treated (control) or stimulated with increasing amounts of melittin for 30 min. Total cell extracts from 
wildtype-MEFs (Wt) and ADAM10-/--MEFs were subjected to immunoblot analysis and stained with a C-
terminal anti-N-cadherin antibody. N-cadherin CTF generation was calculated by densitometric analysis 
of three independent experiments (right panel). Results are expressed as mean ± S.E. (n=3). * Indicates 
significant increase in CTF generation compared to control (* p < 0.05). B: HUVECs were stimulated 
with melittin in the presence or absence of broad-spectrum metalloprotease inhibitor marimastat (MM, 
10 µM). VE-cadherin cleavage was analyzed with a C-terminal VE-cadherin antibody by immunoblot. 
Densitometric analysis of three independent experiments is shown in the right panel (* p < 0.05). 
 
 
To verify these results in another cell type, melittin treated HUVECs were analyzed for VE-
cadherin shedding (Figure 8 B). Melittin induced VE-cadherin shedding at concentrations of 
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0.5 µM and 1 µM. This shedding was inhibited by the broad-spectrum metalloprotease inhibitor 
marimastat (MM). In addition, ADAM17-mediated L-selectin cleavage in humane neutrophil 
granulocytes was analyzed by FACS analysis by our cooperation partners in Mainz (Anja Fries, 
Isabell Cornelsen and Sucharit Bhakdi; Institute of Medical Microbiology and Hygiene, Guten-
berg University Mainz). They could show that 0.5 µM melittin induces a rapid decrease of L-
selectin surface expression and that this decrease was metalloprotease-dependent (see supple-
ments) (Sommer et al., 2012). In conclusion, melittin in sublethal dosages evokes ADAM10- 
and ADAM17-dependent shedding in different cell types. 
 
 
Figure 9: Melittin augments ADAM-dependent E-cadherin shedding. A: After incubation with melit-
tin (Mel), HaCaT cell pellets were subjected to immunoblot analyses using a C-terminal E-cadherin anti-
body. Densitometric analysis of E-cadherin CTF generation was calculated of three independent experi-
ments (right panel). Results are expressed as mean ± S.E. (n=3). B: Cells were pre-incubated with the 
ADAM10 inhibitor GI254023X (GI, 3 µM), the ADAM10/-17 inhibitor GW280264 (GW, 3 µM), the 
metalloprotease inhibitor marimastat (MM. 10µM), or DMSO (D) as control for 10 min before stimula-
tion. E-cadherin CTF generation was calculated by densitometric analyses of three independent experi-
ments (right panel). Melittin significantly increased E-cadherin proteolysis (*, p < 0.05). MM, GI and 




4.1.3. Melittin induces ADAM-dependent E-cadherin shedding and transactivation of 
the EGFR in keratinocytes 
The effect of melittin on HaCaT keratinocytes was then further investigated. In these cells, 
E-cadherin is preferentially cleaved by ADAM10 (Maretzky et al., 2008), while shedding of 
TGF-α is ADAM17-dependent (Peschon et al., 1998). Melittin dose-dependently increased 
E-cadherin shedding (Figure 9 A). The increase was significant at concentrations of 0.5 and 
1 µM.  This effect could be significantly reduced by the use of broadspectrum metalloprotease 
inhibitor marimastat and also by the preferential ADAM10 inhibitor GI245023X (GI) and 
GW280264 (GW), an inhibitor for ADAM10 and -17 (Figure 9 B).  
 
 
Figure 10: Melittin induces EGFR activation in HaCaT keratinocytes. A: Release of TGF-α from 
melittin (Mel) treated HaCaT keratinocytes were analyzed by ELISA and compared to mock treated cells. 
Cells were preincubated with the ADAM10 inhibitor GI254023X (GI, 3 µM), the ADAM10/-17 inhibitor 
GW280264 (GW, 3 µM), the metalloprotease inhibitor marimastat (MM. 10µM), or DMSO (co) as con-
trol for 10 min before stimulation with melittin (Mel, 0.5 µM, 30 min). Data represent mean values of five 
independent experiments with S.E. Melittin significantly increased TGF-α release (**, p < 0.01). This 
effect was significantly decreased by the use of MM and GW (#, p < 0.05; ###, p < 0.001). B: HaCaTs 
were treated with 0.5 µM melittin for 30 min in the presence or absence of marimastat (MM, 10 µM). 
Whole cell lysates were subjected to immunoblot analyses for pEGFR and pERK1/2 respictively. Repre-
sentative westernblots are shown for EGFR phosphorylation and ERK1/2 phosphorylation with EGFR 
and ERK included as loading control. 
 
Melittin simultaneously provoked release of TGF-α in the supernatant as measured by ELISA. 
As expected the release of TGF-α was strongly inhibited by marimastat and the ADAM10 
and -17 inhibitor GW, but only weakly affected by the preferential ADAM10 inhibitor GI 
(Figure 10 A). TGF-α is one of seven EGFR ligands, which is critically involved in cell differ-
entiation, migration and proliferation (chapter 1.2.3) Therefore it followed that melittin stimula-
tion might lead to EGFR transactivation. To test this immunoblots were stained with specific 
antibodies against phosphorylated and unphosphorylated EGFR and ERK respectively. Indeed, 
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exposure of melittin induced EGFR phosphorylation with downstream activation of ERK1/2 
(Figure 10 B). Again, this effect was prevented by the use of marimastat. In summary, melittin 
provokes ADAM-mediated E-cadherin and TGF-α cleavage. This results in EGFR transactiva-
tion and subsequent ERK1/2 phosphorylation. 
 
4.1.4. Melittin induces keratinocyte proliferation and migration 
The result that melittin induces EGFR and ERK1/2 activation in an ADAM-dependent manner, 
suggests that functional consequences might follow the shedding process. To test this hypothe-
sis, proliferation and migration analyses were performed. Incubation of HaCaT keratinocytes 
with melittin resulted in increased proliferation, as determined by propidium iodide (PI) cell 
cycle analysis (Figure 11). Cell cycle analysis was performed by Isabell Cornelsen (Institute of 
Medical Microbiology and Hygiene, Gutenberg University Mainz). The melittin-induced prolif-
eration was comparable to that of recombinant EGF, which was used as positive control and 
was abrogated by the use of TAPI-0, a broadspectrum metalloprotease inhibitor. 
 
Figure 11: Melittin augments metalloprotease-dependent proliferation of HaCaT keratinocytes. 
Cell cycle analysis was done by propidium iodide (PI) staining and flow cytometry. Cells were seeded at 
20,000 cells/well in microtiter plates and stimulated with EGF (4 nM) as positive control and with melit-
tin (0.5 µM). After 24h increased percentages of EGF and melittin treated cells were in S+G2/M phase. 
TAPI-0 (10 µM) abrogated the melittin induce effect. Analyses are representatives of two independent 
experiments (performed by I. Cornellsen, Mainz). 
 
To address the role of melittin in HaCaT keratinocyte migration, an in vitro model for wound 
healing was used. In confluent HaCaT cultures scrape wounds were generated with pipette tips 
and cells were allowed to migrate for 24 h. This assay was performed in the presence of 2 mM 
hydroxyurea to prevent keratinocyte proliferation (Firth and Putnins, 2004). While mock treated 
cells just started to cover the denuded area, melittin treatment lead to almost complete wound 
closure. This effect was abolished in the presence of marimastat or by the use of cetuximab 
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(Figure 12). Cetuximab is a monoclonal antibody, which blocks access of ligands to the EGFR 
preventing EGFR activation. In conclusion, application of melittin in low concentration induces 




Figure 12: Melittin induces migration in HaCaT keratinocytes. Cells were grown to confluence and a 
cell-free area was introduced by scratching with a pipette tip. After washing, cells were mock treated or 
treated with melittin (0.5 µM) in the presence or absence of marimastat (MM, 10 µM) (A) or with the 
EGFR-blocking antibody cetuximab (Cetux, 10 µg/ml) (B). Migration was evaluated after 24 h. Micro-
graphs of one of three independent experiments are shown. Bar: 100 µm. Migration of three independent 
assays are quantified (right panel). Asterisk (*) indicates a significant increase compared to mock treated 
samples (*, p < 0.05, n = 3). MM and Cetux significantly inhibited melittin-induced migration (#, 
p < 0.05, n = 3). 
 
4.1.5. Melittin-induced effects are not due to altered ADAM10/-17 expression, mem-
brane fluidity or cytosolic Ca2+ increase. 
Reiss et al. showed that free fatty acids augmented ADAM-mediated shedding by increasing 
membrane fluidity (Reiss et al., 2011). To rule out that melittin, as membrane-modulating sub-
stance, affects the fluidity of membranes, steady-state fluorescence anisotropy measurements 
were performed. These experiments were done by Gerald Gimpl (Department of Biochemistry, 
Gutenberg-University Mainz). In brief, the diffusion of fatty acyl chains in HaCaT keratinocytes 
was determined using diphenyl hexatriene as a probe. Melittin in concentrations that induced 
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ADAM substrate processing exerted no effects on membrane fluidity (see supplements) (Som-
mer et al., 2012).  
To exclude that melittin-induced effects are due to altered ADAM10 or -17 expression levels or 
maturation, Real-Time PCR (RT-PCR) and immunoblot analysis were performed. This was 
done by Nancy Speck (Institute of Dermatology and Allergology, UKSH Kiel). Melittin treat-
ment did not significantly increase RNA expression or protein levels of ADAM10 and -17 
(Sommer et al., 2012).  
Another possible mechanism for ADAM activation is elevation of cytosolic Ca2+. Melittin stim-
ulation has been shown to stimulate Ca2+ influx in different cell types (Choi et al., 1992; Shar-
ma, 1993). To find out whether extracellular calcium influx would contribute to ADAM activa-
tion, HaCaT keratinocytes were stimulated with increasing amounts of melittin in calcium con-
taining and in calcium-free medium. Cytosolic calcium increase was measured by fluorescence 
spectroscopy (done by Gerald Gimpl, Department of Biochemistry, Gutenberg-University 
Mainz). Intracellular calcium increase was apparent in Ca+-containing and Ca2+-free medium. In 
Ca2+-free medium the cytosolic increase was lower compared to the increase in Ca2+-containing 
medium. This indicated that melittin induced the influx of extracellular Ca2+ as well as release 
of Ca2+ from intracellular stores. In immunoblot analyses for E-cadherin shedding and EGFR 
signaling neither chelation of intracellular nor extracellular calcium affected the cellular re-
sponse (see supplements, Sommer et al., 2012). 
 
4.1.6. Melittin effects depend on ATP-release and P2 receptor activation 
Purinergic P2 receptors are involved in several physiological processes (Erb et al., 2006). They 
are divided in two families, the P2X receptors, which are ATP-gated ion channels and the P2Y 
receptors, which are G-protein-coupled receptors. Both receptor families are able to participate 
in the activation of ADAM-mediated shedding (chapter 1.3.2). HaCaT keratinocytes express 
P2X and P2Y receptors (P2R). Since melittin elicited ATP release the participation of P2 recep-
tors in melittin evoked effects were investigated. Therefore experiments were performed using 
the broad-spectrum P2R inhibitor pyridoxalphosphate-6-azophenyl-2´,4´,-disulfonic acid 
(PPADS). As shown in Figure 13 A, PPADS abolished melittin-induced ERK1/2 phosphoryla-
tion dose-dependently (upper panel). Additionally, melittin induced E-cadherin shedding was 
strongly reduced by PPADS to an extent comparable with marimastat effects (lower panel). 
This result was confirmed by the use of the broad-spectrum P2R inhibitors suramin (Figure 
13 B) and Evans blue (Figure 14A). Both compounds reduced melittin-stimulated E-cadherin 





Figure 13: P2 receptor inhibitors strongly reduced melittin-stimulated shedding of E-cadherin and 
ERK1/2 phosphorylation HaCaT keratinocytes. A: Cells were stimulated with 0.5 µM melittin in the 
presence of increasing amounts of PPADS. Representative western blot analysis of ERK1/2 phosphoryla-
tion with an immunoblot of total ERK1/2 as a loading control is shown in the upper panel. PPADS (PP, 
100 µM) inhibition of melittin-induced E-cadherin shedding was almost as effective as marimastat (MM, 
10 µM) lower panel. B: The P2R antagonist suramin (Sur) decreased melittin-induced ERK1/2 phosphor-
ylation and E-cadherin CTF generation at 100 µM and 200 µM concentrations. One representative im-




To further validate the role of ATP in melittin-induced ADAM activation, HaCaTs were stimu-
lated with melittin in the presence or absence of increasing amounts of the ATPase hexokinase. 
Addition of hexokinase reduced ERK1/2 phosphorylation and E-cadherin shedding dose-
dependently, although the effects were not completely abrogated (Figure 14B). Human embry-
onic kidney 293 (HEK293) cells express only little amounts of P2Y receptors and do not ex-
press P2X receptors (Schachter et al., 1997). These cells showed a strikingly increased response 
to melittin stimulation when transfected with P2X7 (Figure 14 B). This response was abrogated 
by pretreatment with marimastat and by treatment with the ATPase apyrase. Stimulation with 





Figure 14: P2 receptor signalling is involved in activation of melittin effects in HaCaT keratino-
cytes. A: immunoblot analyses for ERK1/2 phosphorylation and E-cadherin C-terminal fragment (CTF) 
generation showed that the P2R inhibitor Evans Blue (EB, 1 µM) strongly reduced the melittin evoked 
effects. B: Cells were treated with 0.5 µM melittin for 30 min with increasing amounts of the ATPase 
hexokinase. Hexokinase dose-dependently reduced melittin-induced ERK1/2 phosphorylation and E-
cadherin CTF generation. C: HEK293T cells were mock-transfected or transfected with P2X7. 48 h af-
terward, cells were stimulated with melittin (0.5 µM) in the presence of marimastat (MM, 10 µM) or 
ATPase apyrase (Ap, 2 units/ml). Stimulation with bzATP was used as positive control. Transfection with 
P2X7 increased melittin-stimulated ERK1/2 phosphorylation, which was abolished in the presence of Ap 












4.2. The role of phosphatidylserine exposure for ADAM17-mediated  
proteolysis  
 
Based on the result that melittin evokes ADAM-mediated shedding in an ATP- and P2-receptor 
dependent manner the hypothesis arises that PtdSer exposure could be a trigger for ADAM acti-
vation. P2 receptor activation, in particular P2X7 activation is known to induce several mem-
brane changes including PtdSer exposure (Qu and Dubyak, 2009). The P2X7-induced PtdSer 
exposure can be irreversible but also transient. The transient PtdSer exposure is important for 
myotube formation and was additionally shown for neutrophils stimulated with chemotactic 
peptides (Frasch et al., 2004; van den Eijnde et al., 2001). The potential role of PdtSer exposure 
for ADAM activation is investigated in this second part of the thesis. 
 
4.2.1. The ADAM10 and -17 stimulants melittin and ionomycin induce fast PtdSer 
exposure 
To analyze if the ADAM10 and ADAM17 stimulants melittin and ionomycin promote PtdSer 
exposure, confocal life cell imaging experiments were performed with the PtdSer probe PSIVA-
IANBD. PSIVA-IANBD is an annexin XII based polarity sensitive dye that fluoresces only 
when it is bound to the cell membrane. HaCaT keratinocyte were seeded in glass-bottom imag-
ing dishes and were grown until semi-confluency. The imaging was performed with an inverted 
confocal microscope (Fluoview FV1000, Olympus) in a humidified atmosphere at 37° C. Cells 
were allowed to rest for at least one hour in the microscope stage. PSIVA-IANBD was added in 
a final concentration of 6.25 µg/ml 5 min before acquisition started. The dye was excited at 
488 nm and emission was recorded at 520 nm every 30 s. After an initial period of 15 min 
melittin or ionomycin was added to a final concentration of 1 µM and the imaging was contin-
ued for further 30 min.  As shown in Figure 15 A and in the supplementary movies, melittin 
induced a fast and transient PtdSer exposure, which spreads almost over the whole cell surface 
and reached a maximum between 10 and 15 min before it slowly declined. The potent ADAM 
activator ionomycin induced a fast PtdSer exposure in the first 5 min followed by a slight eleva-
tion of PtdSer exposure over the whole imaging period (Figure 15 B and supplementary mov-




Figure 15: ADAM-activators melittin and ionomycin induce fast phosphatidylserine exposure. Con-
focal life cell imaging was performed with HaCaT keratinocytes in a humidified atmosphere at 37° C 
using the PtdSer-binding fluorescence probe pSIVA-IANBD. Melittin (1 µM, A) or ionomycin (0.5 µM, 
B) was added 15 min after starting the experiment. Imaging was performed for at least 30 min after addi-
tion of the stimulants. Representive images of melittin or ionomycin treated cells at different time points 
are shown on the left panel (bars represent 10 µm). Mean fluorescence area was calculated by using Im-
ageJ1.47 and corrected for cell growth area (right panel, melittin n=5 ± S.E., ionomycin n=1). 
  
 
4.2.2. Phosphatidylserine exposure correlates with ADAM17-mediated shedding 
The strong PtdSer exposure induced by melittin or ionomycin raised the question if it correlates 
with ADAM-mediated shedding. Therefore, different inhibitors were used, which are known to 
inhibit the most important signaling pathways leading to ADAM17 activation. Cells were ana-
lyzed in parallel for PtdSer exposure and ADAM17 activity. HaCAT keratinocytes were grown 
on coverslips, treated with the ADAM stimulants melittin, ionomyin, PMA or FGF7 with or 
without the corresponding inhibitor and stained afterwards for PtdSer exposure with annexinV-
FITC. In parallel, cells were treated the same way and analyzed for ERK1/2 phosphorylation as 
a read out for ADAM17-mediated shedding (Figure 16). As shown in Figure 16 A, melittin 
induced a strong PtdSer exposure in HaCaT keratinocytes. This exposure was significantly in-
hibited by the P2-receptor antagonist PPADS. For quantification, the mean fluorescence area 
was analyzed of 6-8 images of three independent coverslips for each group with ImageJ1.47 and 
0 min 10 min 30 min







corrected for cell growth area. The obtained data were tested for significance with ANOVA 
analysis and Bonferroni multiple comparison test. In correlation to the PtdSer exposure, melit-
tin-induced ERK1/2 phosphorylation was inhibited by the use of PPADS. Ionomycin elicited 
PtdSer exposure and ERK1/2 phosphorylation was inhibited with the calcium chelator EGTA 
(Figure 16B). The selective ADAM17 activators PMA and FGF7 induced PtdSer exposure that 
was punctuated in contrast to that of melittin and ionomycin (Figure 16 C and D). PMA stimu-
lated PtdSer exposure and ERK1/2 phosphorylation was inhibited with the PKC inhibitor stau-
rosporin. FGF7 induced PtdSer exposure and ERK1/2 phosphorylation were inhibited by the 
src-kinase inhibitor PP2. In summary, inhibition of ADAM17 activation correlated with inhibi-





Figure 16: ADAM activators induce PtdSer exposure and correlating ERK1/2 phosphorylation. 
Inhibitors targeting the signaling of these stimulants decrease significantly PtdSer exposure and 
ERK1/2 phosphorylation. HaCaTs were grown on cover slips and mock treated (control, co), pretreated 
with the indicated inhibitors PPADS (100 µM), EGTA (10 mM), staurosporine (1 µM) or PP2 (10 µM) 
for 15 min before addition of the stimulants melittin (A, 1 µM), ionomycin (B, 1 µM), PMA (C, 300 
ng/ml) or FGF7 (D, 100 ng/ml) respectively. Cells were stimulated for 15 min and immediately stained 
with annexinV-FITC for PtdSer exposure. Representative images of each group are shown on the left 
(bars represent 10 µm). Image analysis was done with ImageJ1.47m. Fluorescence area above back-
ground was determined and correlated to the cell growth area. For each group three independent co-
verslips, each with 6-8 images of different areas were analyzed (ANOVA, Bonferroni multiple compari-
son post test: *, p<0.05; **, p<0.01; ***, p<0.001). pERK immunoblot analysis were undertaken in paral-
lel experiments as readout for ADAM17 sheddase function. One representative blot out of three is shown 
on the right side. 
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4.2.3. Inhibition of phosphatidylserine exposure abolish ADAM17-mediated shedding 
To prevent PtdSer exposure in cells the stilbene disulfonate derivative 4,4 -diisothio-
cyanatostilbene-2,2-disulfonic acid (DIDS) was used.  The inhibition of PtdSer translocation 
was verified by confocal life cell imaging with the PtdSer binding probe PSIVA-IANBD. DIDS 
is known as universal nonspecific Cl–-channel inhibitor that block Ca2+-activated and volume-
regulated Cl– channels and anion exchangers. In cortical neurons and cardiomyocytes DIDS was 
shown to prevent apoptotic cell shrinkage and mildly attenuated cell death induced by various 
apoptotic stimuli without affecting caspase activation and DNA damage (d'Anglemont de Tas-
signy et al., 2008; Malekova et al., 2007; Wei et al., 2004). Beside these effects DIDS is often 
used as PtdSer scrambling inhibitor. It abolishes P2X7-induced PtdSer exposure and conse-
quently CD62L shedding in lymphocytes (Elliott et al., 2005).  Modulation of Ca2+ homeostasis 
may cause these effects as experiments in red blood cells (RBCs) stimulated with ionomycin 
indicate (Kucherenko et al., 2013).  HaCaT keratinocytes stimulated with melittin (0.5 µM) and 
imaged with the PtdSer probe PSIVA-IANBD exhibited fast and transient PtdSer exposure 
(Figure 17 A). Pretreatment of HaCaT with 100 µM DIDS completely abolished melittin-
induced PtdSer exposure (Figure 17 B and supplementary movies). In contrast to solely melittin 
treated cells, DIDS together with melittin treated cells appeared to be rounded.  
 
Figure 17: DIDS inhibits melittin-induced PtdSer exposure: Confocal life cell imaging was performed 
with HaCaT keratinocytes in a humidified atmosphere at 37° C using the PtdSer-binding fluorescence 
probe pSIVA-IANBD. A: HaCaT keratinocytes were treated with 1 µM melittin. B: Cells were preincu-
bated for 10 min with DIDS (100µM) and afterwards stimulated with 1µM melittin at timepoint 0. Repre-
sentive images of melittin and melittin + DIDS treated cells at different time points are shown (bars rep-
resent 10 µm). 
0 min 5 min 10 min 15 min
Meli  nA
0 min 5 min 10 min 15 min
Meli  n + DIDSB
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To analyze the effect of DIDS on stimulated ADAM17-mediated shedding, HaCaT keratino-
cytes were stimulated in the presence and absence of DIDS and marimastat with melittin, iono-
mycin, PMA and FGF7 and were analysed for ERK1/2 phosphorylation. As shown in Figure 18 
A, all stimuli increased ERK1/2 phosphorylation similar to what observed before. These in-
creases in ERK1/2 phosphorylation were inhibited by preincubation with marimastat or DIDS. 
This indicates that DIDS may inhibit ADAM17 proteolytic function by inhibiting PtdSer expo-
sure. This result was confirmed in HUVECs (Figure 18 B), which were stimulated in the pres-
ence or absence of DIDS or marimastat with ionomycin, PMA and the physiological ADAM 
stimuli thrombin and analysed for TNFR1 shedding. Again, pretreatment of the cells with 
marimastat or DIDS significantly reduced the stimulated shedding of TNFR1.  
 
 
Figure 18: DIDS inhibits ADAM17-mediated ERK1/2 phosphorylation in HaCaT keratinocytes and 
TNFR1 shedding in HUVECs. A: HaCaTs were mock treated (-, co), pretreated with the indicated in-
hibitors marimastat  (MM, 10 µM) or DIDS (100 µM) for 15 min before addition of the stimulants melit-
tin (1 µM), ionomycin (1 µM), PMA (300 ng/ml) or FGF7 (100 ng/ml) respectively for 15 min. Subse-
quently cells were analysed for ERK1/2 phosphorylation by immunoblotting. B: HUVECs were mock 
treated (co), pretreated with marimastat (MM, 10 µM) or DIDS (100 µM) and stimulated with ionomycin 
(1 µM), PMA (100 ng/ml) or thrombin (Thr, 5 U) for 1 h. Conditioned supernatant was afterwards ana-
lysed for soluble TNFR1 by ELISA (n = 3, ANOVA, Boferroni multiple comparison post test: Asterisks 
indicate significance in stimulation, octothorps indicate significance in inhibition. */# p<0.05; **/## p< 
0.01; *** /###p<0.001.). 
 
Due to the observed morphological changes induced by DIDS another inhibitor was used to 
verify the results obtained with DIDS. SITS (4-Acetamido-4′-isothiocyanato-2,2′-
stilbenedisulfonic acid) is like DIDS a stilbene derivate that is used to inhibit PtdSer exposure 
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with comparable pharmacological properties as DIDS (Cytlak et al., 2013; Kucherenko et al., 
2013). HaCaT keratinocytes exhibited less PtdSer exposure upon melittin stimulation when 
pretreated with SITS (Figure 19 A). To investigate if SITS also inhibits ADAM17-mediated 
shedding, HaCaT keratinocytes were treated with melittin (1 µM) or PMA (300 ng/ml) for 1h in 
the presence or absence of SITS or marimastat and analyzed for TNFR1 shedding. As expected, 
SITS strongly reduced TNFR1 shedding. Although the effect of DIDS and SITS on ADAM-
mediated shedding and PtdSer exposure were not tested for all stimuli, cell types and read outs, 
the results obtained so far clearly indicate that both inhibitors can block PtdSer exposure and 
ADAM17-mediated shedding. 
 
Figure 19: SITS inhibits PtdSer exposure and TNFR1 shedding in HaCaT keratinocytes. A: Ha-
CaTs were grown on cover slips and mock treated (control), pretreated for 15 min with SITS (0.5 mM) 
before melittin (1 µM) was added. Cells were stimulated for 15 min and immediately stained with an-
nexinV-FITC for PtdSer exposure. Representative images of one experiment are shown (bars represent 
10 µm). B: HaCaT keratinocytes were mock treated (co), pretreated with marimastat (MM, 10 µM) or 
SITS (1 mM) and stimulated with melittin (1 µM), respectively PMA (300 ng/ml) for 1 h. Conditioned 























4.2.4. Cells defective in PtdSer synthesis exhibit reduced PtdSer externalisation and 
decreased ADAM17-mediated shedding of TGF-α 
Mammalian cells contain two PtdSer synthases (PSS). PSS1 can synthesize PtdSer from PtdCho 
and PSS2 synthesizes Ptdser from PtdEtn (Figure 20). PSA3 is a mutant CHO-K1 cell line de-
fective in PSS1 activity. When PSA3 cells are cultured in the absence of exogeneous PtdSer the 
cellular PtdSer level decreases (Kuge et al., 1986). This PtdSer reduction can be avoided by 
supplementing the cells with exogenous ethanolamine, which drives the PtdSer synthesis in an 
PSS2-dependent manner (Kuge and Nishijima, 1997; S. Lee et al., 2012).  
 
 
Figure 20: Biosynthetic pathway of PtdSer in mammals. Mammals contain two PtdSer synthases 
(PSS). PSS1 and -2 synthesize PtdSer by exchanging the headgroup of PtdCho or PtdEtn for serine. 
PtdEtn is generated by a multistep synthesis from ethanolamine and PtdCho from choline. 
 
 
To analyze the PtdSer exposure the cells were either cultured in medium supplemented with 
dialyzed FCS and ethanolamine or for PtdSer reduction in medium supplemented only with 
dialyzed FCS. After 96 hours cells were stimulated with ionomycin or melittin and analyzed by 
PSIVA-IANBD live cell imaging for PtdSer exposure (supplementary movies). Representative 
images of starved (w/o Etn) or supplemented cells (+Etn) of ionomycin treated cells are depict-
ed in Figure 21 A. Fluorescence area quantification of ionomycin or melittin treated cells is 
shown in Figure 21 B, respectively C (left side). In parallel, cells cultured identically were 
transfected after 72 h with TGF-α-AP and stimulated after 96 h with ionomycin or melittin. The 
ADAM17-mediated relative increase of stimulated TGF-α-AP shedding was determined as de-
scribed. (Figure 21 B and C, right side). Starving of PSA3 cells resulted in less PtdSer exposure 
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and in significantly reduced TGF-α-AP processing compared to unstarved cells after stimulation 
with ionomycin or melittin (Figure 21). 
 
 
Figure 21: Starved PSA3 cells show decreased PtdSer exposure upon stimulation and decreased 
ADAM17 activity. PSA3 cells were PtdSer deprivated by starving in HamsF12 medium with 6% dia-
lyzed FCS with or without ethanolamine for 96 h. A: Representative images of unstarved (+Etn) or 
starved (w/o Etn) PSA3 cells stimulated with ionomycin (1 µM) and analysed with pSIVA-IANBD con-
focal life cell imaging for PtdSer exposure (bars represent 10 µm). B and C: Fluorescence area quantifi-
cation of starved and unstarved ionomycin (B) or melittin (C) treated PSA3 cells, stained with the PtdSer 
probe pSIVA-IANBD (left side). In parallel starved and unstarved TGF-α-AP transfected PSA3 cells 
were analyzed for ADAM17-dependent TGF-α-AP processing upon stimulation and compared to untreat-
ed controls (right side, unpaired t-test: *, p< 0.05; **, p< 0.01). 
 
 








4.2.5. Structural basis for ADAM17-phosphatidylserine interaction 
ADAM17 sheds its substrates directly above the cell surface. A hypothetic interaction of AD-
AM17 with PtdSer could pull down the metalloprotease domain ensuring the correct positioning 
of the protease to the substrate. Proteins that bind to acidic phospholipids often share some spe-
cific characteristics. This includes pattern of polybasic amino acids near to a membrane anchor. 
To validate if ADAM17 fulfills these criteria the sequences of acidic phospholipid binding pro-
teins were compared with the sequence of ADAM17. As shown in Table 19 the membrane 
proximal domain of ADAM17 contains several basic amino acids. This pattern resembles the 
motifs of other acidic phospholipid binding proteins, for example Raf-1. 
 
Table 19: Sequence comparison of ADAM17 and proteins binding to acididc phospholipids. The 
amino acid sequence of the membrane proximal domain of ADAM17 (MPD17) is compared to sequences 
of proteins that are able to bind to acidic phospholipids. Basic amino acids are marked in blue. 
Protein	   Polybasic	  sequences	  binding	  to	  acidic	  phospholipids	  
MPD17	   581FCKREQELESCACVDTDNSCKVCCRNLSGPCVPYVDAEQKNLFLRKGKPCTVGFCDMNGKCE642	  
Raf-­‐1	   141FARKTFLKLAFCDICQKFLLNGFRCQTCGY170	  
Rac1	   171EAIRAVLCPPPVKKRKRKCL190	  
Src	   2GSSKSKSKPKDPSQRRR16	  
RALA	   184SKEKNGKKKRKSLAKRIRECCIL206	  
EGFR	   645RRRHIVRKRTLRRLLQ660	  
MARCKS	   145KKKKKRFSFKKS156	  
K-­‐Ras4B	   174GKKKKKKSKTSC185	  
HIV-­‐1	  Gag	   2GARASVLSGGELDRWEKIRLRPGGKKKYKL31	  
 
The membrane proximal domain of ADAM17 exists in two forms, the flexible/open and the 
inflexible/closed conformation. The three-dimensional structure of the closed MPD was solved 
by heteronuclear NMR spectroscopy by Düsterhöft et al. in 2013 (Figure 22 A, right side). Due 
to the flexibility of the open conformation in the lower PDI-sensitive part (C600XXC603) no 
NMR structure is solved. To get an idea about how the charges of the MPD could be distributed, 
the structures of the human and murine MPD were analyzed for electrostatic potentials. The 
structures were prepared with the PDB2PQR tool of the UCSF chimera software package using 
the CHARMM force field method and the electrostatic potential map was calculated with the 
Adaptive Poisson-Boltzmann Solver (APBS) (Baker et al., 2001; Dolinsky et al., 2007; 2004; 
MacKerell et al., 1998; Unni et al., 2011). Even though the calculations were performed with 
the closed conformation of the MPD, the electrostatic surface coloring indicates that the basic 
amino acids R625K626XK628 in the flexible part may contribute to PtdSer binding through electro-




Figure 22: Structure and electrostatic potential of the closed membrane proximal domain of AD-
AM17. A: Schematic model of ADAM17 (MP: metalloprotease domain; Dis: disintegrin-like domain; 
MPD: membrane proximal domain; CANDIS: conserved ADAM17 dynamic interaction sequence; TMD: 
transmembrane domaine; CT: cytotail) and the three-dimensional structures of the closed conformation of 
the MPD resolved by Düsterhöft et al., 2013. B and C: Left side: structure of the human and murine 
MPD with positively charged amino acids in blue and negatively charged amino acids in red. Right side: 
electrostatic surface map of the human and murine MPD. The structures were prepared with the 
PDB2PQR tool of the UCSF chimera software package using the CHARMM force field method and the 
electrostatic potential map was calculated with the Adaptive Poisson-Boltzmann Solver (APBS). Electro-
static potential is shown as gradient from -10 (red) to +10 (blue). The polybasic motif (R625K626XK628), 

























4.2.6. The membrane proximal domain of ADAM17 binds to phosphatidylserine 
Assuming that the PtdSer interactions take place in the membrane proximal domain of AD-
AM17 the interaction of recombinant MPD with PtdSer and PtdCho liposomes was analyzed. In 
cooperation with C. Nehls and T. Gutsmann (FZ Borstel, Department of Biophysics) isothermal 
titration calorimetry (ITC) and surface acoustic wave (SAW) measurements were performed. In 
the ITC experiments the MPD was titrated with PtdSer-liposomes or with PtdCho:PtdSer (9:1) 
liposomes. As shown in Figure 23 A, titration of the open MPD with PtdSer liposomes led to an 
exothermic reaction, as indicated by a downward signal at every titration step. This indicates a 
considerable reactivity of the MPD with PtdSer liposomes, whereas this reaction is significantly 
lower when titrating with PtdCho-liposomes. Interestingly, conversion of the open MPD to a 
closed confirmation by PDI treatment, almost completely abrogated PtdSer liposome interaction 
(Figure 23 B), indicating that the PtdSer binding motif is located in the N-terminal flexible part of 
the MPD. 
The binding of the open MPD to PtdSer was confirmed by surface acoustic wave biosensor 
measurements (Figure 23 C). In short, SAW chips were coated with the indicated liposomes and 
buffer containing the MPD was applied. An increase in the amplitude signal indicates a higher 
mass loading of the chip, indicating a binding of the MPD to the liposomes. The amplitude and 
phase shift diagram shows that the MPD interacts with PtdSer liposomes but not with PtdCho 





Figure 23: The membrane proximal domain of ADAM17 binds to Ptdser. A and B: Isothermal titration 
calorimetry measurements to study the interaction of the open (A) and closed (B) form of the MPD with either PtdSer 
(green) or PtdCho (red) liposomes. The MPD (0.5 mM dissolved in 5 mM HEPES, pH 7.4) was titrated 20 times in 
1.5 µl injections into 250 µl of the respective lipid solution (0.1 mM dissolved in 5 mM HEPES, pH 7.4) at 22 °C and 
the heat of the interaction were recorded. The final lipid:protein ratio was 5:3 [M:M]. An upwards signal indicates a 
exothermic reaction of the open MPD with PtdSer liposomes. C: Binding of the open form of the ADAM17 MPD to 
the CM-dextran/PLL functionalization of sensor chip surfaces (black) and to additionally immobilized PtdSer mem-
branes (green) or to PtdCho:PtdSer (9:1) membranes (red) in SAW biosensor experiments. Shown is the average 
phase shift ΔΦ (top) of five individual sensor channels indicating a mass loading on the surface and the average 
amplitude shift ΔA (bottom) indicating a decrease of viscosity. (Lena Heinbockel and Christian Nehls from FZ Bor-
stel performed these experiments).  
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4.2.7. O-Phospho-L-serine inhibits ADAM17 activation 
Phosphatidylserine consists of diacylglycerol, saturated or unsaturated fatty acids and the hy-
drophilic phosphoserine headgroup. When ADAM17 activation is due to direct interaction with 
PtdSer in the membrane, the exogenously applied soluble headgroup of PtdSer O-phospho-L-
serine (OPLS) should inhibit ADAM17 activation competitively. To test this hypothesis, HaCaT 
keratinocytes were stimulated in the presence or absence of increasing amounts of OPLS, or the 
headgroup oft PtdCho phosphocholine (PC) and analyzed for ADAM17-dependent ERK1/2 
phosphorylation (Figure 24 A). To verify that ERK1/2 phosphorylation was metalloprotease 
dependent, the general metalloprotease inhibitor marimastat (MM) was used as an additional 
control. As shown in Figure 24 A, PMA-induced ERK1/2 phosphorylation was dose-
dependently inhibited with OPLS and a complete inhibition were observed with 10 mM. In con-
trast to OPLS, PC had no effect on PMA-induced ERK1/2 phosphorylation. To confirm this 
result, primary umbilical vein endothelial cells (HUVECs) were stimulated with PMA, ionomy-
cin or melittin in the presence or absence of OPLS or PC and the supernatant was analyzed for 
soluble TNFR1 (Figure 24 B). The membrane receptor TNFR1 is a substrate for ADAM17 and 
is shed after ADAM17 activation (Reddy et al., 2000). Stimulation of the cells with the indicat-
ed stimuli led to a 4- to 8-fold increase of soluble TNFR1 in the supernatant. This increase was 
significantly inhibited in the presence of OPLS, but not with PC (Figure 24 B). 
 
Figure 24: Competition of ADAM17-phosphatidylserine interaction abrogates ADAM17 activity. 
A: HaCaT keratinocytes were stimulated with PMA (300ng/ml) for 30 min and subsequently analyzed for 
ADAM-dependent ERK1/2 phosphorylation by immunoblot. PMA-induced ERK1/2 phosphorylation was 
dose-dependently reduced by addition of the PtdSer headgroup O-phospho-l-serine (OPLS). In contrast, 
phosphocholine (PC), the headgroup of PtdCho, did not reduce ERK1/2 phosphorylation. One representa-
tive immunoblot out of three is shown.  B: Primary endothelial cells (human umbilical veine endothelial 
cells, HUVECs) were analyzed for ADAM17-dependent TNFR1 shedding by ELISA. PMA (200ng/ml), 
ionomycin (IO, 1 µM) and melittin (Mel, 1 µM) induced a strong increase in TNFR1 shedding measured 
after 1 h that was significantly inhibited with OPLS (10mM) but not with PC (10mM) (n = 5, ANOVA, 
Boferroni multiple comparison post test: Asterisks indicate significance in stimulation, octothorps indi-
cate significance in inhibition. */# p<0.05; **/## p< 0.01; ***/### p<0.001). 








4.2.8. The polybasic motif R625K626XK628 of ADAM17 is necessary for stimulated and 
constitutive shedding of TGF-α 
The electrostatic modeling and the finding that the open, but not the closed form of the MPD 
bind to PtdSer indicates that the polybasic motif R625K626XK628 could be responsible for AD-
AM17 PtdSer interaction. This motif is located in the N-terminal flexible part of the MPD in 
close proximity to the CANDIS and the transmembrane domain. To verify if this motif is in-
volved in modulating ADAM17 activity, the basic amino acids were substituted with glycine by 
site-directed mutagenesis in a murine ADAM17 plasmid. This mutant (A17 3x) was transfected 
in ADAM17 and ADAM10 double-deficient murine MEFs. These cells were analyzed for con-
stitutive and stimulated shedding of TGF-α-AP (Figure 25 A-C). The mutagenesis and in parts 
the AP-assays were done by F. Kordowski (Institute of Dermatology and Allergology, UKSH 
Kiel; as part of his work as PhD student). The ADAM17 stimulant PMA induced a strong in-
crease in TGF-α-AP release in wildtype ADAM17 transfected cells. The A17 3x mutant lost its 
ability to shed TGF-α-AP almost completely in a manner that was comparable to that of the 
inactive E/A ADAM17 variant (Figure 25 A). Additionally, melittin and ionomycin induced 
TGF-α-AP processing was significantly lower compared to wildtype ADAM17 (Figure 25 B). 
To answer the question if only the stimulated shedding is affected by the mutated polybasic 
motif, the constitutive TGF-α-AP processing was determined over 6 h. As shown in Figure 25 C 
the constitutive shedding of the 3x mutant is almost completely abolished to an extent compara-
ble to the E/A mutant. In summary, despite a similar expression level (not shown), the 3x mu-
tant loses the ability to shed TGF-α-AP. TGF-α-AP resembles the natural occurring ADAM17 
substrate TGF-α, which is a transmembrane protein that is cleaved in close proximity to the 
membrane. To elucidate if the 3x mutant is still proteolytically active, experiments with a solu-
ble metalloprotease substrate were performed. This peptide is based on the TNF-α sequence and 
carries a quenched fluorophore that can be detected after cleavage. ADAM17 wildtype, 3x and 
the E/A variant were overexpressed in highly transfectable Cos-7 cells and incubated for 6 h in 
the presence of the fluorogenic substrate. As shown in Figure 25 D, overexpression of the 3x 
mutant increased the substrate processing almost to the same level as wildtype ADAM17, indi-
cated by an increase in fluorescence. Overexpression of the E/A variant did not increase sub-
strate processing. The increase of fluorescence was metalloprotease-dependent as shown by the 




Figure 25: ADAM17 lacking the polybasic motif (R625, K626, K628) loses the ability to shed the 
transmembrane substrate TGF-α even though it is able to cleave soluble peptides. The inactive mu-
rine ADAM17 variant E/A, the wildtype murine ADAM17 or the mutated murine ADAM17 3x (R625, 
K626, K628, each substituted to G; upper scheme) were transfected together with TGF-α-AP to AD-
AM10 and -17-deficient murine embryonic fibroblasts (A-C, performed by F. Kordowski; Institute of 
Dermatology and Allergology, UKSH Kiel). The TGF-α-AP shedding rate was determined after 2 h of 
PMA stimulation (200 ng/ml; A), 1 h of melittin (1 µM) or ionomycin (1 µM; B) or after 6 h of untreated 
cells (C) and compared to their related controls (ADAM17 wt transfected, untreated cells). D: Cos7 cells 
were transfected with ADAM17 E/A, wt or 3x respectively and incubated with a soluble fluorogenic 
ADAM substrate with or without marimastat (MM, 10 µM). The fluorescence of the cleaved peptide in 
the supernatant was measured after 6 h of incubation and compared to untransfected cells. The data show 
the mean ± S.E. of 5 independent experiments and were testet for statistical significance with ANOVA 
Boferroni multiple comparison post test (Asterisks indicate significance in stimulation, octothorps indi-












5.1. Melittin modulates keratinocyte function through P2-receptor-
dependent ADAM activation 
 
The bee venom component melittin has been discussed as promising supplement for anti-
microbial, anti-inflammatory and anti-cancer therapy (Duclohier, 2010; Oršolić, 2012). It was 
shown that melittin selectively destroys cancer cells in vitro and it was tested in animal models 
for hepatocellular carcinoma, breast cancer and prostate cancer, with positive outcome (Liu et 
al., 2008; Son et al., 2007). Other investigations revealed that melittin enhances permeability in 
CaCo-2 epithelial cell monolayers and that melittin provokes proliferation of gastrointestinal 
cells (Maher et al., 2007; Maher and McClean, 2008). Both are physiological events that are 
often associated with ADAM-mediated shedding of cell adhesion molecule and release of 
EGFR-ligands. Therefore, the aim was to investigate the effects of melittin on ADAM-mediated 
substrate release and consecutively the functional consequences. It is demonstrated that subcy-
totoxic melittin concentrations evoked a rapid up-regulation of ADAM10 and -17 functions in 
different celltypes. This was mediated by ATP-release from the cells and subsequent P2-
receptor activation. In HaCaT keratinocytes, this finally lead to the functional consequences of 
de-adhesion, migration and proliferation.  
 
5.1.1. Melittin in sublethal concentration induces ATP-release from cells 
Little is known about the molecular mechanisms of the melittin action. A cellular receptor is not 
known to exist, instead melittin binds via its cationic domain to the membrane and this is fol-
lowed by membrane insertion of the hydrophobic part (Dawson et al., 1978). Additionally, 
melittin induces the release of marker molecules from liposomes (Sessa et al., 1969). In analogy 
with poreforming toxins, this could indicate that melittin oligomers may be able to form trans-
membrane pores. Consistent with this theory, it is shown in this thesis, that melittin, even in 
sublethal dosages, evoked ATP-release in a nanomolar concentration range. However, how ATP 
is released and how sufficient concentrations of ATP should accumulate to trigger P2-receptor 
response is not clear. Different mechanisms are known to trigger ATP-release from cells. To 
these belong stretch, osmolarity changes, oxidative stress and microbial products (Schwiebert 
and Zsembery, 2003). In conclusion, beside the possible pore-forming properties of melittin, 
ATP-release could also occur as a normal physiological stress response. Moreover, P2X7 acti-
vation leads to Pannexin-1 pore formation through which ATP release could occur, so that a 
self-amplifying activation loop may be created (Baroja-Mazo et al., 2013).  
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5.1.2. Melittin induces ADAM-dependent substrate cleavage 
This investigation focuses on the two major members ADAM10 and -17 of the ADAM family. 
Subtoxic melittin treatment enhanced substrate processing of both proteases. In different cell 
types cadherins, a classical ADAM10 substrate family, were cleaved after melittin stimulation. 
To these belong N-cadherin in MEFs, VE-cadherin in endothelial cells and E-cadherin in Ha-
CaT keratinocytes. Shedding of N-cadherin results in diminished adhesive behavior and redis-
tribution of β-catenin in the cells (Reiss et al., 2005); cleavage of VE-cadherin increases vascu-
lar permeability and leukocyte transmigration (Schulz et al., 2008); shedding of E-cadherin pro-
vokes loss of epithelial cell-cell contacts and is associated with eczematous dermatitis 
(Maretzky et al., 2008; 2005). The result that ADAM10 is responsible for the melittin-induced 
N-cadherin cleavage was confirmed by the use of ADAM10-deficient MEFs, which showed no 
shedding of N-cadherin upon melittin stimulation. These findings that melittin induces AD-
AM10-mediated cadherin cleavage would provide retrospectively an explanation for the report 
that melittin enhances permeability of CaCo-2 epithelial cell monolayers (Maher et al., 2007). 
Besides ADAM10 activation, melittin stimulation also provoked processing of ADAM17 sub-
strates. In HaCaT keratinocytes soluble TGF-α was ADAM17-dependent significantly increased 
after melittin stimulation. Additionally, also in leukocytes melittin stimulated shedding of the 
ADAM17 substrate L-selectin. These data together indicate that melittin truly can be seen as an 
ADAM10 and -17-activator, that works independent of the cell type and the kind of substrate. 
Further analysis is required to reveal if melittin is a broad-spectrum metalloprotease activator 
not only affecting ADAM10 and -17. 
 
5.1.3. Melittin induces keratinocyte proliferation and migration 
ADAM17 sheds a large subset of substrates. To these belong inter alia the EGFR ligands TGF-
α, HB-EGF and amphiregulin (Sahin et al., 2004). Activation of the EGFR cascade causes cell 
proliferation and migration (Koivisto et al., 2006). Melittin induced shedding of TGF-α in Ha-
CaT keratinocytes. This resulted in EGFR and subsequently ERK1/2 activation. Since all EGFR 
ligands are released through proteolysis, it is quite likely that also other ligands contribute to the 
observed EGFR activation. In any case functional consequences would follow. The functional 
consequences were confirmed by proliferation and migration analyses of melittin stimulated 
HaCaT keratinocytes. Both were significantly enhanced in a metalloprotease and EGFR-
dependent manner. This is of particular interest because melittin is considered as a anti-tumor 
agent (Duclohier, 2010; Oršolić, 2012). Detailed analysis using specific inhibitors or siRNA 
would be required to determine the proportion of ADAM10 and -17 or even additional proteases 
to these processes. Nevertheless, melittin in subcytotoxic concentrations evoked proliferation 
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and migration in these cells. This finding is in line with the reported melittin-induced prolifera-
tion of gastrointestinal cells (Maher and McClean, 2008). With regard to the usefulness of 
melittin as anti-cancer agent, these results bring these approaches into question. 
 
5.1.4. Melittin effects depend on ATP-release and P2-receptor activation 
Different approaches were undertaken to elucidate the pathway leading to ADAM activation by 
melittin.  Biophysical membrane properties may participate in controlling ADAM function by 
influencing the velocity of molecular movements in the lipid bilayer. Enhancement of mem-
brane fluidity by free unsaturated fatty acids increases ADAM-mediated substrate processing 
(Reiss et al., 2011). Although melittin is known to disturb membranes, no changes in membrane 
fluidity were observed. A prime candidate for ADAM-activation is intracellular calcium eleva-
tion (Horiuchi et al., 2007b; Le Gall et al., 2010). It was already shown that melittin induces 
Ca2+-influx and PLA2-activation in ras-transformed cells (Sharma, 1993). In this thesis, melittin 
induced dose-dependently cytosolic Ca2+-elevations by extracellular influx and by depletion of 
intracellular Ca2+-stores. Interestingly, neither chelation of intracellular or extracellular Ca2+ was 
sufficient to prevent ADAM-mediated substrate processing. Although not shown, inhibition of 
PLA2, PLC and PKC did not prevent ADAM-mediated substrate shedding. The fact that ATP is 
released after melittin treatment and that P2-receptors can contribute to ADAM function turned 
the focus to these receptors. It was shown that ADAM-dependent shedding of L-selectin and 
CD23 from human leukemic B-cells is inducible by extracellular ATP (Gu et al., 1998; Ja-
mieson et al., 1996). Additionally, P2X7 is responsible for inducing cleavage of CD23 and 
CD27, two important mediators of the immune system (H. Moon et al., 2006; Sluyter et al., 
2007). In those studies, supra-physiological ATP concentrations were used to stimulate ADAM-
mediated functions. This point differs from the mechanism of melittin-induced ADAM-
mediated shedding proposed here. Melittin in subtoxic concentrations induced ATP release at 
nanomolar concentrations. Concentrations, which would not be sufficient to induce ADAM-
mediated shedding in experiments with extracellular applied ATP. However, since the cells 
themselves release ATP, it is probable that the local ATP concentration at the cell surface is 
much higher before it gets diluted in the supernatant. Three lines of evidence proved the in-
volvement of ATP and P2-receptors in melittin-induced ADAM function. At first, PPADS, Ev-
ans blue and suramin, three commonly employed inhibitors of purinergic receptors suppressed 
melittin-mediated ADAM activation. Second, transfection of P2X7 in HEK293 increased melit-
tin-induced ADAM function. Third, the melittin-induced ADAM-mediated shedding was re-
duced in the presence of ATPases. 
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Although not very specific, PPADS, Evans blue and suramin are commonly used to inhibit P2-
receptors (Lambrecht, 2000; Ralevic and Burnstock, 1998). Whereas suramin and Evans blue 
block P2-receptor in general, PPADS exhibits more specifity towards P2X-receptors. To further 
validate the role P2-receptors in melittin-induced ADAM function P2X7 was transfected into 
HEK293 cells. Hek293 are widely used as model to investigate the role of P2-receptors, because 
they express only low amounts of P2Y receptors and do not express P2X receptors (Schachter et 
al., 1997). Overexpression of P2X7 in Hek293 remarkably increased the response to melittin 
stimulation. This indicates that at least P2X7 is important for the melittin-induced ADAM-
activation. Due to the diversity and complexity of the purinergic receptor families, no further 
analyses were done to elucidate the contribution of individual receptors to the melittin-evoked 
effects.  Most likely other P2 receptor contribute to the melittin response, eventually by modu-
lating the signals leading to ADAM activation. One study highlights the role of P2Y2 in modu-
lating intracellular Ca2+ responses to inflammatory stimuli. Rowlands et al. demonstrated that 
P2Y2 prolonged mitochondrial Ca2+ elevations in mouse lung micro vessels upon TNF-α stimu-
lation and that this contributed to ROS generation and TNFR1 shedding (Rowlands et al., 2011). 
Additionally, the contribution of ROS to the melittin-induced ADAM activation cannot be ex-
cluded. Melittin can induce release of ROS and ROS can activate ADAM-mediated shedding 
(Myers et al., 2009; Stuhlmeier, 2007). 
The role of ATP in the melittin-induced P2-receptor response was demonstrated by addition of 
ATPases to melittin treated cells. The different ATPases apyrase and hexokinase both reduced 
melittin-induced ERK1/2 phosphorylation. The ERK1/2 phosphorylation was not completely 
abrogated by ATPases, indicating that either the sufficiency was not enough or other additional 
mechanisms may play a role. One report suggests that melittin additionally interacts directly 
with transmembrane proteins (Keith et al., 2011). It might be speculated that direct binding of 
melittin to P2 receptors can occur to modulate their activation. A similar mechanism has been 
proposed for the antimicrobial peptide LL37 (Wewers and Sarkar, 2009). The studies on the 
role of this peptide in P2-receptor and EGFR activation showed striking similarities with the 
melittin-induced effects described here (Tokumaru et al., 2005; Tomasinsig et al., 2008). Both 
induce transient ATP release in the absence of overt cytotoxicity (Elssner et al., 2004). Both 
induce functions which are P2-receptor dependent and at least, both exhibit migration and pro-
liferation promoting functions (Tokumaru et al., 2005; Tomasinsig et al., 2008).  
 
5.1.5. Model of melittin evoked ADAM10 and -17-mediated substrate release 
In conclusion, it was shown in this investigation that melittin in subcytotoxic concentrations is a 
general ADAM10 and -17-mediated shedding activator. This downstream event of melittin 
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leads to diverse functional consequences depending on the cell target. In HaCaT keratinocytes 
melittin induces de-adhesion, migration and proliferation, which puts the therapeutic potential 
of melittin as an anti-cancer agent into question. Since ADAM17 is the prime TNF-α processing 
enzyme, the anti-inflammatory potential of melittin should also be reconsidered. The proposed 




Figure 26: Melittin induces ADAM10- and -17-mediated substrate processing in an ATP and P2-
receptor dependent manner. Melittin stimulation leads to ATP egress, which in turn activates P2X and 
P2Y receptors. Activation of these receptors induces multifaceted signaling cascades. To these belongs 
for example intracellular Ca2+-elevation, Phospholipase activation (e.g. PLC, PLD, cPLA2), protein ki-
nase activation (e.g. PKC), K+-efflux and mitochondrial ROS generation. Through not yet defined mech-
anisms ADAM10 and -17 are than activated and shed their substrates. These substrates can be cell-
adhesion molecules and EGFR-ligands. Shedding of these substrates leads to the functional consequences 
of de-adhesion, proliferation and migration. 
 
Melittin evokes its effect by releasing ATP from the cells by a mechanism that is not yet fully 
solved. One possibility is that melittin forms pores by which ATP egress. This ATP would acti-
vate purinergic receptors leading to diverse signaling events. These include cytosolic and mito-
chondrial Ca2+-elevation, K+-efflux, phospholipase activation, cAMP decrease and kinase acti-
vation. The mechanisms leading than to ADAM activation will be discussed in more detail in 
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concentration elevations, which are not chelated by EGTA or BAPTA-AM, mitochondrial ROS 
generation or potassium efflux. 
However, melittin induces ADAM-mediated shedding in a P2-recpetor dependent manner. 
Which P2-receptors are involved may differ in different cell types due to the different expres-
sion pattern. The different receptors would lead to different signaling cascades, which might 
lead to ADAM-activation, which is different in time-course, strength and localization. Finally 
this would lead to substrate and tissue specific effects with yet unpredictable functional conse-
quences. In HacAT keratinocytes these functional consequences of melittin stimulation were 





5.2. The role of phosphatidylserine exposure for ADAM17-mediated 
proteolysis 
ADAM17-mediated shedding is upregulated by several physiological and unphysiological stim-
uli. The fast increase in substrate release is independent of the intracellular part of ADAM17 
(Le Gall et al., 2010). Rather than intracellular ADAM17 modulations, the membrane seems to 
play an important role in determining ADAM17 activity. The impact of membrane modulations 
in determining ADAM17 activity was shown in the context of ADAM17 localization in the 
membrane, raft disruption and membrane fluidity. Despite these findings, the final trigger for 
ADAM17 activation was unknown. One possible mechanism for membrane-dependent inside-
out signaling leading to ADAM17 activation is phosphatidylserine translocation from the inner 
leaflet to the outer leaflet of the membrane. Therefor the aim of this investigation was to exam-
ine the role of phosphatidylserine exposure on ADAM17 activation.  
In this thesis it has been demonstrated that activators of ADAM17-mediated shedding lead to 
PtdSer exposure and that this correlates with the proteolytic activity of ADAM17. Inhibition of 
PtdSer externalization either by reducing the PtdSer contents of cells or by using inhibitors di-
minished ADAM17-mediated shedding. Assuming a direct interaction of PtdSer with AD-
AM17, the ability of the membrane proximal domain of ADAM17 to bind to PtdSer was proven 
by in vitro analyses. In functional shedding analyses, competition for PtdSer binding with the 
soluble head group of PtdSer decreased significantly ADAM17-mediated substrate release. 
Moreover, mutating the probable PtdSer-binding motif of ADAM17 completely abolished stim-
ulated and constitutive shedding. 
Taken together, these findings lead to the final model that PtdSer exposure serves as ultimate 
trigger for ADAM17-activation. ADAM17 binds via its polybasic motif to PtdSer ensuring the 
right positioning of ADAM17 to its substrate and this finally enables the shedding events. These 
results and conclusions will be discussed in more detail in this chapter. 
 
5.2.1. Phosphatidylserine exposure correlates with ADAM17-mediated shedding 
As shown by live cell imaging and annexinV staining, the ADAM17 stimuli melittin, ionomy-
cin, PMA and FGF7 induced PtdSer exposure in cells. Except ionomycin, all stimuli lead to a 
transient externalization of PtdSer. This was characterized by a time-dependent increase fol-
lowed by a decrease in fluorescence. This PtdSer translocation correlated with ADAM17-
mediated ERK1/2 phosphorylation. Most important, specific signaling inhibitors inhibited Pdt-
Ser translocation as well as ERK1/2 phosphorylation. No direct link between PtdSer exposure 
and ADAM activation is reported. However, several stimuli, which are described to induce 
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ADAM-mediated shedding, are often also described to induce PtdSer exposure. In the literature, 
permanent PtdSer exposure is the classical hallmark of apoptosis (Martin et al., 1995). Apopto-
sis is a suicidal process that occurs during all stages of life (M. D. Jacobson et al., 1997; Raff et 
al., 1994). During apoptosis ADAM-mediated shedding of the membrane proteins IL6R, E-
cadherin, L-selectin, TNFR1 and CD46 was observed (Chalaris et al., 2007; Hakulinen and 
Keski-Oja, 2006; Madge et al., 1999; Steinhusen et al., 2001; Walcheck et al., 2006). In this 
thesis ionomycin induced a fast and permanent PtdSer exposure accompanied by ADAM-
mediated shedding. Ionomycin has been shown to induce apoptosis in different cell types and it 
is often used as potent ADAM10 and -17 activator (Garbers et al., 2011; Möller-Hackbarth et 
al., 2013; Stasik et al., 2007; Takei and Endo, 1994).  In contrast to ionomycin, melittin induced 
PtdSer exposure was transient. As shown in the first part of this thesis melittin stimulated ATP- 
and P2-receptor-dependent ADAM10 and -17 substrates release. Both, ATP and P2 receptors, in 
particular P2X7, are reported to induce PtdSer exposure (Qu et al., 2009; Sluyter et al., 2007). 
Additionally, P2-receptor activation induces ADAM-mediated shedding of TNF-α, TNFR1 and 
L-selectin (Elliott et al., 2005; Le Gall et al., 2009; Rowlands et al., 2011).  In contrast to iono-
mycin and melittin, the selective ADAM17 activators PMA and FGF7 induced punctuated 
PtdSer spots, which were located at the cell boarders. PMA is a PKC activator that is often used 
to induce fast ADAM17-mediated shedding (Le Gall et al., 2010). It also induces PKC-
mediated Ca2+-influx and PtdSer exposure in red blood cells (Andrews et al., 2002; Nguyen et 
al., 2011). The growth factor FGF7 has recently been described to induce ADAM17-mediated 
EGFR signaling (Maretzky et al., 2011a). Here, it is shown for the first time that PMA and 
FGF7 induce PtdSer exposure in nucleated cells. If this punctuated PtdSer exposure is exclu-
sively typical for ADAM17 activation and if this pattern resembles membrane micro domains 
needs to be further validated, it is conceivable that staining of ADAM17 and/or its substrates 
would yield in a co-staining with PtdSer. 
Interestingly, inhibition of the signaling cascades of the above-mentioned ADAM activators, 
decreased not only ADAM17-mediated ERK1/2 phosphorylation, it also inhibited PtdSer expo-
sure. Also, other ADAM stimuli are reported to induce PtdSer exposure. These include fMLP, a 
chemotactic factor derived from bacteria, thrombin, a serine protease, or LL-37, an antimicrobi-
al peptide. fMLP was shown to induce L-selectin shedding from neutrophils and also to induce 
PtdSer exposure at uropod rafts in neutrophils (Ball and King, 2011; Frasch et al., 2004). 
Thrombin causes PtdSer exposure in platelets in an TMEM16F-dependent mechanism (van 
Kruchten et al., 2013). Additionally, thrombin induces ADAM17-mediated shedding of GPIbα 
from platelets (Bergmeier et al., 2004). The antimicrobial peptide LL-37 induces caspase-
independent PtdSer externalization and also ADAM-mediated transactivation of the EGFR (Ren 
et al., 2012; Tjabringa et al., 2003; Tokumaru et al., 2005; Tomasinsig et al., 2008). 
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The underlying general mechanisms of PdtSer exposure are complex and not well understood. 
Lipid scramblases are under suspicion to participate in the stimulus and apoptosis-induced 
PtdSer exposure. Lipid scramblases are often Ca2+-activated lipid transporters, which randomize 
lipids between the leaflets and counteract ATP-dependent flippases upon activation (Pomorski 
and Menon, 2006). In red blood cells and platelets PLSCR1 is involved in PtdSer exposure, 
which activates blood clotting and phagocytosis (Bassé et al., 1996; Bevers et al., 1982; Com-
furius et al., 1996; Zhou et al., 1997). However, mouse blood cells from PLSCR1-deficient mice 
were still able to scramble phospholipids. This indicates that PLSCR1 is not solely responsible 
for PtdSer exposure (Zhou et al., 2002). Until now five PLSCR (PLSCR1-5) have been identi-
fied (Wiedmer et al., 2000). In conjunction with other scramblases, for example TMEM16F and 
Xkr8, they may contribute to PtdSer exposure (Kmit et al., 2013; Suzuki et al., 2013a; 2014; 
2010). TMEM16F, also known as anoctamin6, is a transmembrane Ca2+-activated Cl--channel 
(Kunzelmann et al., 2009). Beside this action, it was shown that TMEM16F is also an inward 
rectifying unselective ction channel and a PtdSer scramblase itself (Kunzelmann et al., 2009; 
2014; Suzuki et al., 2010; van Kruchten et al., 2013).  Patients of the rare Scott syndrome carry 
a loss-of-function mutation in the TMEM16F gene in platelets and other hematopoietic cells. 
These cells are unable to perform Ca2+ -dependent phosphatidylserine exposure and, hence, are 
impaired in supporting blood coagulation (Suzuki et al., 2010). If these cells are defective in 
ADAM-mediated substrate release is currently unknown. Xkr8 is a recently identified apopto-
sis-related scramblase that is activated by caspase-3 cleavage (Suzuki et al., 2013a). This 
scramblase contributes to the late PtdSer exposure in apoptosis and is at least not directly regu-
lated by calcium.  
Nevertheless, most of the known scramblases are thought to be Ca2+-dependent (Bucki et al., 
2001; Suzuki et al., 2013b). Beside Ca2+-dependent scramblase activation, inhibition of flip-
pases might also contribute to PtdSer exposure. ATP-dependent flippases, including family 
members of P-type-ATPases and ABC-transporters, are maintaining the lipid asymmetry be-
tween the membrane leaflets (Pomorski and Menon, 2006). Due to the complex network of 
phospholipid scrambling and flipping with its multifaceted possibilities of regulations, one 
could speculate that the ADAM stimulants might culminate in signaling events that drive PtdSer 





Figure 27: ADAM stimuli signaling lead to PtdSer scrambling. The multifaceted signaling cascades of 
ADAM activators culminate in the end in PtdSer exposure. The mechanisms involved are complex and 
not yet understood. Thrombin activates GPCRs of the protease activated receptor family. Depending on 
the G-proteins, are cAMP-levels downregulated, rho/ras activated or Ca2+-released from the ER leading to 
complex downstream events. Melittin leads to ATP egress from the cells and this activates P2-receptors 
(Figure 26). In the case of P2X7 activation, this increases Ca2+-influx and K+-efflux. PMA mimicks di-
acylglycerol and activates PKCs, which in turn initiate diverse signaling cascades and Ca2+-release. 
FGFR2b signaling leads to src kinase activation and activation of many downstream effector molecules. 
In these signaling cascades plays often Ca2+ a role, but also kinases and ROS may contribute to the ob-
served PtdSer exposure. Although not known, the PdSer scrambling is most likely due to scramblase 
activation and flippases inhibition.  
 
 
5.2.2. Inhibition of PtdSer translocation diminished ADAM17-mediated substrate 
release 
The correlation of PtdSer exposure and ADAM17-mediated ERK1/2 phosphorylation indicates 
that PdtSer exposure might be a trigger for ADAM17 activation. This was evaluated by inhibit-
ing PtdSer translocation with DIDS. DIDS is a unspecific Cl--channel and anion exchanger 
blocker, which is additionally often used to prevent PtdSer externalization (Elliott et al., 2005; 
Kucherenko et al., 2013). DIDS treatment of stimulated cells prevented PtdSer scrambling as 
well as ADAM17-mediated substrate release. The underlying mechanism of DIDS in preventing 
PtdSer exposure is not known. A recent study indicates that DIDS is not able to modulate Ca2+ 
homeostasis, at least in RBC stimulated with ionomycin (Kucherenko et al., 2013). This indi-












































inhibits anion channels by covalently binding to specific amino acids in the channel pore 
through two isothiocyanate groups (Bridges et al., 1989; Laver and Bradley, 2006). These NH2-
specific crosslinking can probably also occur with other proteins, such as scramblases- hence 
inhibiting PtdSer exposure. Unfortunately, it cannot be ruled out that DIDS affect ADAM17 or 
its substrate directly by crosslinking them. Therefore the effect of DIDS on ADAM17-mediated 
shedding was confirmed with the DIDS derivate SITS. SITS has only one isothiocyanate group 
and no potential to crosslink primary amines, but exhibits comparable pharmacological proper-
ties as DIDS (Cytlak et al., 2013; Kucherenko et al., 2013). Indeed, SITS suppressed PtdSer 
exposure and ADAM17-mediated TNFR1 release in HaCaT keratinocytes. These findings sup-
ported the results obtained with DIDS, especially in the context that SITS is reported to inhibit 
PtdSer exposure (Cytlak et al., 2013). Due to the limitations of pharmacological approaches to 
inhibit PtdSer exposure these studies were not intensified. Instead, PSA3 cells were used to 
proof the concept that PtdSer scrambling directly induces ADAM17-mediated shedding. PSA3 
cells, a CHO-K1 cell line defective in PSS1, showed reduced PtdSer exposure and TGF-α-AP 
shedding upon ionomycin and melittin treatment when starved without ethanolamine. This 
starving results in a decreased cellular level of PtdSer (Kuge et al., 1986). Beside its transloca-
tion from the inner to the outer leaflet of membranes, PtdSer has several intracellular functions. 
To these belong ionic interactions with proteins, for example with Rho, Rac and src. PtdSer 
binding of these proteins is important for their function (Finkielstein et al., 2006; Lemmon, 
2008; Sigal et al., 1994). Additionally, PtdSer plays a role in targeting proteins to phagosomes 
(Yeung et al., 2009). Due to these roles of phosphatidylserine, intracellular side effects that 
might affect ADAM17 activation cannot be ruled out when the cellular PtdSer content decreas-
es. However, in all experiments, PtdSer externalization correlated with ADAM17-mediated 
shedding. 
 
5.2.3. The membrane proximal domain of ADAM17 binds to PtdSer 
Proteins that bind to PtdSer typically contain polybasic amino acids at their binding site (Lem-
mon, 2008; L. Li et al., 2014). The membrane proximal domain of ADAM17 contains several 
basic amino acids, which might contribute to the assumed binding to PtdSer. The potential bind-
ing ability for PtdSer was identified by sequence comparison of proteins that bind to PtdSer 
with that of ADAM17 and by electrostatic surface calculations. Even though, sequence compar-
ison and electrostatic calculations are just an approximation, it indicates that the polybasic motif 
R625K626XK628 located in the flexible part of the MPD is the most probable interaction site for 
PtdSer binding. The MPD exists in a flexible/active form and can be inactivated by PDI-induced 
reshuffling of disulfide bridges (Düsterhöft et al., 2013). The electrostatic calculations were 
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performed on the only structure available, the inactive/closed MPD and can therefore not reflect 
the real situation. Nevertheless, the most promising region for interactions with PtdSer is in the 
part of the MPD that is in the open form highly flexible. This flexibility would facilitate interac-
tions with PtdSer rather than hinder them. 
The ability of the MPD to bind to PtdSer was confirmed by in vitro isothermal titration calorim-
etry (ITC) and surface acoustic wave (SAW) experiments. Titrating PtdSer containing lipo-
somes with the open/flexible MPD resulted in a considerably exothermic reaction. The 
closed/inflexible MPD showed no binding reaction to these liposomes. This indicates that only 
the open MPD of ADAM17 is able to bind to PtdSer. In SAW experiments, the modulation of a 
surface-confined acoustic wave is utilized for the analysis of surface binding. Biomolecular 
interaction processes on the surface of the sensor chip can result in changes of phase and ampli-
tude of the surface acoustic wave. Changes of these parameters correlate with mass loading and 
viscoelastic alterations (Andrä et al. 2008). In these experiments, the recombinant MPD in its 
flexible/open conformation bound at physiological conditions preferential to PtdSer containing 
liposomes, indicated by an increase in mass loading and a decrease in viscosity. Together this 
led to the hypothesis that ADAM17 binds to exposed PtdSer with its flexible MPD.  
 
5.2.4. Competing for PtdSer binding decreases ADAM17-mediated shedding 
The hypothesis that PtdSer exposure serves as trigger for ADAM17 activation by a direct inter-
action was further validated by using the soluble head group of PtdSer as competitor. OPLS is 
often used to inhibit the phagocytosis of PtdSer exposing cells (Ohnishi et al., 2010). In this 
case, OPLS competes with the binding sites for PtdSer on phagocyting cells, thus preventing 
phagocytosis (Stolzing and Grune, 2004). In the ADAM17 stimulation experiments, OPLS 
dose-dependently inhibited ADAM17-mediated shedding in HaCaT keratinocytes and HU-
VECs. In contrast, PC the head group of the uncharged PtdCho had no effect on ADAM17-
mediated shedding. This indicates that there is a specific interaction between ADAM17 and the 
head group of PtdSer. In conclusion, OPLS competes with the binding site for PtdSer in AD-
AM17, abrogating the interaction of ADAM17 with exposed PtdSer in the membrane.  
 
5.2.5. The polybasic motif of ADAM17 is necessary for shedding of transmembrane 
substrates 
To further validate this hypothesis, the polybasic motif was mutated to uncharged glycines in 
ADAM17 expression plasmids. This mutated A17 3x was transfected into ADAM10/17 double 
deficient MEFs and shedding analyses were performed. Mutating basic amino acids to prevent 
possible ionic binding interactions is a common tool to study the specificity and functional con-
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sequences of the binding. For example, it was used to identify the binding of src and the T-cell 
receptor cytoplasmic tail to acidic phospholipids (Sigal et al., 1994; C. Xu et al., 2008). Even 
the expression level was comparable to wildtype ADAM17, the 3x mutant almost completely 
lost the ability to shed TGF-α in AP-assays. In contrast, this mutant was still able to cleave sol-
uble fluorogenic ADAM substrates. That indicates that the bona fide proteolytic potential of 
ADAM17 3x is not impaired. Interestingly, also the constitutive shedding of the 3x mutant was 
almost completely abolished. This could be due to the unresponsiveness to low amounts of 
spontaneous PtdSer exposure. It is worth speculating that nanoscale PtdSer exposure in the local 
environment of ADAM17 would be sufficient to induce shedding. This nanoscale PtdSer expo-
sure cannot be detected with conventional confocal microscopy due to the diffraction limit. 
Those nanoscale lipid environments for membrane proteins were discovered for caveolin-1 and 
the T-cell receptor. Both are accompanied by acidic lipids in the inner leaflet, which is neces-
sary for the proper function of these proteins (Ariotti et al., 2014; Molnár et al., 2012; Shi et al., 
2013). Together, this leads to the conclusion that the ADAM17 proteolytic activity is triggered 
by binding of ADAM17 to exposed PtdSer. 
 
5.2.6. Model of ADAM17 activation 
Based on the findings of this thesis, a model for ADAM17 activation is proposed. ADAM17-
mediated substrate cleavage is triggered by PtdSer translocation from the inner to the outer leaf-
let. Ionic interactions between the positively charged amino acid motif, located in the membrane 
proximal domain of ADAM17 and negatively charged PtdSer pulls the metalloprotease domain 
down. This enables the active site to reach the cleavage site of the substrate, which is for all 
substrates located in close proximity to the membrane. This model explains the ultimate activat-
ing step for ADAM17-mediated substrate release (Figure 28). 
Proteins, which interact with negatively charged phospholipids, have generally three character-
istics in common. They bind via fast ionic attraction, followed by a slow integration of hydro-
phobic amino acid side chains into the membrane. At least, this binding occurs for almost every 
protein in close proximity to a membrane anchor (Lemmon, 2008; McLaughlin and Murray, 
2005). These membrane anchors can either be myristoyl anchors, GPI anchors or even a trans-
membrane domain. In a recently submitted report, Düsterhöft et al. could show that the CAN-
DIS domain of ADAM17 is able to integrate into lipid membranes via insertion of hydrophobic 
amino acids. This would stabilize the active confirmation of ADAM17 proposed here, which 
resulted by ionic interactions with PtdSer. In conclusion, ADAM17 fulfills all three criteria of a 
peptide interacting with membrane lipids. It is anchored in the membrane, it interacts ironically 




Figure 28: Schematic model of the final activation step of ADAM17-mediated substrate release. 
Phosphatidylserine translocation from the inner to the outer membrane leaflet enables ionic interactions 
with the polybasic motif of ADAM17. The membrane proximal domain of ADAM17 (MPD) adheres to 
the membrane and pulls the metalloprotease domain down to the cleavage site of the substrate. This con-
formation is stabilized by subsequent integration of the CANDIS domain into the membrane.   
 
 
The conclusions of this thesis are based on in vitro and cell-based assay with different cell 
types. Most of the experiments were done in humane keratinocytes, primary endothelial cell, 
mouse embryonic fibroblasts and monkey fibroblast-like cell lines. These cells cover a broad 
range of cell types and reflect the diversity of tissue composition. This together with the inter 
species conserved MPD and CANDIS region in mammals, indicates that the proposed model of 
ADAM17 activation can probably be generalized. All stimuli led to PtdSer activation. This 
demonstrates that the final trigger for ADAM17-mediated proteolytic shedding is independent 
of the kind of stimuli. This raises the question how substrate selectivity, tissue specificity and 
varying functional consequences can be obtained when all stimuli culminate in PtdSer exposure. 
First, this model explains the final step leading to ADAM17-mediated substrate processing. 
Therefore the substrate should be already in close proximity to ADAM17, if not bound to the 
protease. This selection of the substrates may need specific signaling events as it was shown for 
TGF-α, HB-EGF, or AREG (Dang et al., 2013). Thus, ADAM17 shedding activators may act 
two-sided: On one hand by making the substrate available for shedding, and on the other hand 
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contribute to tissue specific substrate selectivity (Maretzky et al., 2013). In conclusion, substrate 
and tissue specificity of shedding events are obtained by the availability of the substrates, their 
localization and by signaling events that directs the substrates to the proteases. Additionally, the 
signaling that induces PtdSer exposure may vary in their characteristics and localization be-
tween different stimuli and/or tissues because of different expression of ion channels, different 
scramblases or flippases and of the ADAMs and substrates.  
The proposed model describes for the first time the final triggering mechanism for ADAM17-
mediated substrate release and underlines the importance of the membrane composition and 
dynamics in cell function. A better understanding of this membrane dynamics would allow to 
specifically influencing pathological situations with high ADAM17 proteolytic activity. Cancer 
cells and the supplying blood vessels are known to have high rates of exposed PtdSer. In the 
context of ADAM-mediated EGFR-signaling and enhanced proliferation and migration, this 
would provide one explanation of increased ADAM17 activity in cancer.  
Finally, ADAM17 is the first transmembrane protein, which activity is extra-cellularly regulated 
by binding to acidic phospholipids. If also other transmembrane proteins, such as ADAM10, 
interact with exposed PtdSer needs to be evaluated. The unspecific ADAM stimuli ionomycin 
and melittin are known to induce ADAM10-mediated substrate release and as shown in this 
thesis also PtdSer exposure. Although ADAM10 is lacking a polybasic motif in its membrane 
proximal domain, it is possible that there might be another mode of interaction with PtdSer, e.g. 
like annexins via Ca2+ -bridges. In general, transient and locally restricted PtdSer exposure 
could be a signaling mechanism also for other transmembrane and membrane associated pro-
teins. This would be a new mechanism of inside-out signaling of cells, which expands the 






In the first part of this thesis, it was demonstrated that the bee venom component melittin 
evokes ADAM10 and -17-mediated substrate processing, even in subcytotoxic concentrations. 
These shedding events were ATP- and P2-receptor dependent and led to the functional conse-
quences of de-adhesion, proliferation and migration in HaCaT keratinocytes. How melittin in-
duces ATP release is not clear and needs further investigations. Possible mechanisms are either 
the pore forming properties of melittin or the direct binding of melittin to proteins, such as P2-
receptors. A direct activation of P2X7 would lead to pannexin pore formation and subsequent 
ATP release, which would facilitate the melittin-induced cell response. 
Since some antimicrobial peptides are described to induce ADAM-mediated functional conse-
quences, it would be of interest to investigate if this is a common feature of all AMPs and how 
this could work. Most of the AMPs are small cationic peptides. It is possible that they share a 
specific sequence or structure motif that is needed for the proper function and may contribute to 
ADAM activation. By using a synthesized peptide with antimicrobial and ADAM-activating 
properties, which was generated by Klaus Brandenburg (FZ Borstel), it would be possible to 
identify the sequence or structure responsible for its action. Therefore peptides with deleted or 
exchanged amino acids should be generated and tested for the ability to activate ADAM-
mediated proteolysis.  
 
In the second part of this thesis it was demonstrated that PtdSer exposure serves as final trigger 
for ADAM17-dependent substrate release. This is mediated by ionic interactions between nega-
tively charged PtdSer and a polybasic motif of ADAM17. To further validate and extend our 
knowledge of this process additional approaches are considered as useful. Although the 
R625K626XK628 motif is most likely the motif mediating the ionic binding, this should be verified. 
For example by mutating this motif in an MPD17-expression plasmid. This mutated MPD 
should be tested for the ability to bind to PtdSer by using the already established binding anal-
yses described in chapter 4.2.6.  
Moreover, the connection between ADAM-mediated shedding in apoptotic processes and 
PtdSer exposure should be analyzed in detail. It is imaginable that inhibiting PtdSer exposure in 
apoptosis without affecting apoptosis itself would prevent ADAM-mediated shedding. Joscha 
Büch studied this question in parallel for his MD thesis. The results obtained so far are totally in 
accordance with the results and hypothesis described in this thesis. 
In this context a Ba/F3 cell line with a constitutively active scramblase TMEM16F should be 
analyzed for altered ADAM-mediated shedding as well as the physiological relevant B-cells 
from Scott patients, which do not expose PtdSer. Taken together, these experiments would pro-
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vide additional support for the already obtained results and consolidate the role of PtdSer for 
ADAM-mediated substrate shedding. 
Genetically modified mice, expressing ADAM17 without the polybasic motif, would be of par-
ticular interest to define the physiological role of the PtdSer-ADAM17 interaction. The ques-
tions to be solved are: is the interaction of ADAM17 and PtdSer absolutely required for normal 
development? Or, is the activity of ADAM17 just reduced, maybe comparable to ADAM17ex/ex 
mice (Chalaris et al., 2010). These mice are generated with the Crispr/Cas approach together 
with our cooperation partner R. Sedlacec (Prague). Depending on the phenotype of these mice, 
more analyses should be done to evaluate the physiological role of ADMA17-PtdSer interac-
tion. 
A quite challenging issue is how PtdSer is exposed and which are the underlying mechanisms. 
The complex network of signaling and the not well-understood contributions of the different, so 
far identified, scramblases and flippases to this process, make it conceivable that there is more 
than one final mechanism. Different ADAM stimuli may lead to different ways of PtdSer expo-
sure that probably vary between cells and cell types. A good starting point would be to evaluate 
the contribution of a specific scramblase, such as TMEM16F to PtdSer exposure upon trigger-
ing the cells with different ADAM stimuli and analyse the shedding events. The already men-
tioned B-cells of Scott patients, pharmacolocical and siRNA approaches are here the methods of 
choice. 
Another question, which remains to be solved, is the tissue-, substrate- and stimuli-specificity of 
ADAM-mediated functions. ADAMs exerts different functions in different tissues and in differ-
ent stages of development. The mentioned different kind of PtdSer exposure mechanisms may 
also contribute to substrate selectivity. At least three kinds of substrate selection mechanisms 
are imaginable. The substrate itself should be made available for cleavage. This includes signal-
ing that targets the substrate and protein-interaction partners, which directs the substrate to the 
destined location. For some substrate it has been reported that they directly interact with the 
ADAM-protease by binding. Protein-binding partners and/or lipid environments could addition-
ally regulate this process. Once the substrate is available for the ADAM, the shedding is initiat-
ed by PtdSer scrambling, which in turn could also differ in localization and intensity. Taken 
together, due to this complex, diverse and multifaceted signaling that leads to regulated ADAM-
mediated shedding, many questions remain unsolved and should be addressed in further investi-
gations. 
In a broader context, transient PtdSer exposure could be a general signaling mechanism that also 
affects other transmembrane or membrane-associated proteins. It would be of particular interest 
to look for those proteins with polybasic amino acid clusters in close proximity to the outer 
membrane leaflet and analyze their function in response to PtdSer exposure.  
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In summary, although the final triggering step for ADAM17-mediated shedding was figured out 
in this thesis, many open questions remain with regard to the mechanism of PtdSer exposure, 
the substrate selectivity and the generalization of PtdSer exposure as a new extracellular signal-
ing mechanism for membrane-associated proteins.  
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7. Summary  
The “a disintegrin and metalloproteases” (ADAM) -10 and -17 play pivotal roles in various 
physiological and pathophysiological situations. They are responsible for the proteolytic pro-
cessing and release of many cell adhesion molecules, inflammatory cytokines, growth factors 
and receptors. To these substrates belong inter alia cadherins, selectins, TNF-α, EGFR-ligands 
as well as the receptors for VEGF and TNF-α. This wide variety of substrates requires that the 
activity of these proteases is tightly regulated. Indeed, the proteolytic activity of ADAM10 and 
ADAM17 can be rapidly upregulated by certain stimuli. Several studies indicate that different 
signaling processes are involved in this regulation, including kinase activation, elevation of 
intracellular Ca2+-concentrations and interations with protein binding partners. Interestingly, the 
cytotail of ADAM17 as well as the cytotail of ADAM10 is dispensable for stimulated shedding. 
Therefore, other signaling mechanisms than modifications at the cytotail must be responsible for 
the rapid activation of ADAM10 and -17 proteolytic substrate processing. One candidate is the 
cell membrane itself. A recent study showed that the membrane fluidity affects the proteolytic 
release of ADAM substrates. The aim of this thesis was thus to investigate the influence of 
membrane modulations on ADAM-mediated shedding.  
In the first instance, the impact of the membrane disturbing bee venom component melittin on 
ADAM10 and -17 mediated shedding was analyzed. Melittin is an antimicrobial peptide that is 
also being considered as an anti-inflammatory and anti-cancer agent. Shedding analyses re-
vealed that melittin increases the release of ADAM10- and ADAM17-substrates. In HaCaT 
keratinocytes, the shedding of EGFR-ligands led to EGFR activation and consequently ERK1/2 
phosphorylation. Together with E-cadherin shedding, this strikingly increased migration and 
proliferation of these cells. Melittin was shown to elicit these effects via ATP-release and sub-
sequent P2-receptor activation. Degradation of extracellular ATP by ATPases, as well as inhibi-
tion of P2-receptors significantly decreased melittin evoked ADAM-mediated shedding. In Hek 
293T cells, which lack the P2X7 receptor, retransfection of this receptor remarkably enhanced 
the responsiveness to melittin in terms of ADAM-dependent ERK1/2 phosphorylation. In con-
clusion, melittin modulates cellular functions through activation of ADAM-mediated shedding. 
Thus, the use of melittin as drug supplement may elicit unexpected and unwanted effects via 
ADAM activation.  
In the second part of this thesis, the role of phosphatidylserine exposure on ADAM17-mediated 
shedding was analyzed. Phosphatidylserine is a negatively charged phospholipid, which is pri-
marily localized at the cytoplasmic site of membrane bilayers. Upon activation of scramblases 
or inhibition of flippases, phosphatidylserine can rapidly be exposed, a process often, but not 
exclusively associated with apoptosis. It could be shown in this thesis, that all tested ADAM17-
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stimuli induce phosphatidylserine scrambling in cells. This exposure was, except for ionomycin, 
temporary and transient. Moreover, phosphatidylserine exposure correlated with ADAM17-
mediated ERK1/2 phosphorylation and could be inhibited by specific inhibitors, which inhibit 
the signaling cascades that lead to ADAM17 activation. The correlation of phosphatidylserine 
exposure and ADAM17-mediated shedding was additionally proven by either decreasing the 
cellular phosphatidylserine content in cells and by inhibiting the exposure with the stilbene 
derivates DIDS and SITS. Like other phosphatidylserine binding proteins, ADAM17 contains a 
polybasic amino acid cluster (R625K626XK628), which is located in the extracellular membrane 
proximal domain. In in vitro binding assays it was shown that this domain binds to phosphati-
dylserine- but not to phosphatidylcholine-liposomes. Competition for the phosphatidylserine 
binding of ADAM17 with the soluble head group of phosphatidylserine OPLS, competitively 
inhibited ADAM17-mediated shedding. Exchanging the positively charged amino acids to un-
charged amino acids by mutation completely abrogated the shedding of transmembrane sub-
strates whereas the proteolytic potential to cleave a soluble substrate was unaffected. In conclu-
sion, phosphatidylserine exposure serves as final trigger for ADAM17-mediated substrate pro-
cessing. The binding of ADAM17 to phosphatidylserine probably orientates the metalloprotease 
domain to the cleavage site of the substrate and enables the shedding. This propagated model of 
ADAM17-phosphatidylserine interaction describes for the first time the final triggering step for 
ADAM17-mediated substrate processing. In this context, ADAM17 is the first transmembrane 









Die “A Disintegrin and Metalloproteases” (ADAM) -10 und -17 spielen eine entscheidende 
Rolle in vielen physiologischen und pathophysiologischen Prozessen. Sie sind verantwortlich 
für die Freisetzung verschiedenster Transmembranproteine wie zum Beispiel Cadherine, Selek-
tine, TNF-α, EGFR-Liganden und die Rezeptoren für VEGF und TNF-α. Aufgrund dieser Viel-
zahl an Substraten ist es notwendig, dass die proteolytische Aktivität von ADAM10 und -17 
genau reguliert ist. Diverse physiologische Stimulanzien können diese proteolytische Aktivität 
sehr schnell erhöhen. Obwohl die Mechanismen, die der proteolytischen Aktivität von 
ADAM10 und -17 zu Grunde liegen, kaum verstanden sind, zeigen einige Studien, dass insbe-
sondere eine Steigerung der intrazelluläre Ca2+-Konzentration, Kinase-Aktivierungen und Inter-
aktionen mit Protein-Bindungspartnern daran beteiligt sind. Interessanterweise sind die zyto-
plasmatischen Domänen von ADAM10 und auch ADAM17 für das stimulierte Shedding nicht 
notwendig. Deshalb können intrazelluläre Modifikationen von ADAM10 und -17 nicht die Ur-
sache für die schnelle Aktivierung der Protease-Aktivität sein. Stattdessen könnte die Membran 
eine wichtige Rolle spielen, da unter anderem gezeigt wurde, dass die Membranfluidität die 
Sheddingrate beeinflusst. Ziel dieser Arbeit war es deshalb, den Einfluss von Membranverände-
rungen auf das von ADAM10 und -17 vermittelte Shedding näher zu untersuchen.  
Im ersten Teil der Arbeit wurde der Einfluss von Melittin auf die von ADAM10 und -17 vermit-
telte Substrat-Freisetzung untersucht. Melittin ist ein Hauptbestandteil des Bienengiftes und 
beeinflusst die Membran-Integrität, da es sich in die Membranen einlagern kann. Gleichzeitig 
werden Melittin anti-inflammatorische und anti-kanzerogene Eigenschaften zugeschrieben.  
Es wurde gezeigt, dass Melittin die Freisetzung sowohl von ADAM10-, als auch von ADAM17-
Substraten erhöht. In HaCaT Keratinozyten führte das Shedding von EGFR-Liganden zu einer 
Aktivierung des EGFR und einer nachgelagerten Phosphorylierung von ERK1/2. Zusammen 
mit dem Shedding von E-Cadherin führte dies zu einer erhöhten Migration und Proliferation der 
Zellen. Das Melittin-induzierte Shedding von ADAM10- und -17-Substraten war dabei abhän-
gig von ATP-Freisetzung und P2-Rezeptor Aktivierung. In Zellen, die keinen P2X7-Rezeptor 
exprimieren führte die Retransfektion dieses Rezeptors zu einer erhöhten Melittin-induzierten 
ADAM-abhängigen ERK1/2 Phosphorylierung. Zusammenfassend lässt sich sagen, dass Me-
littin das Shedding von ADAM-Substraten aktiviert und damit zelluläre Funktionen beeinflusst. 
Gerade im Hinblick auf den potentiellen therapeutischen Einsatz von Melittin könnte das zu 
unerwarteten und ungewollten Nebenwirkungen führen. 
Im zweiten Teil dieser Arbeit wurde die Rolle von der Externalisierung von Phosphatidylserin 
auf das ADAM17-vermittelte Shedding untersucht. Phosphatidylserin ist ein negativ geladenes 
Phospholipid, dass überwiegend auf der zytoplasmatischen Seite von Zellmembranen lokalisiert 
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ist. Durch die Aktivierung von Scramblasen oder Inhibierung von Flippasen kann Phos-
phatidylserin sehr schnell externalisiert werden, ein Prozess der häufig, aber nicht ausschließlich 
mit Apoptose in Verbindung steht. Es konnte in dieser Arbeit gezeigt werden, dass alle unter-
suchten ADAM17-Stimulanzen auch eine Phosphatidylserin-Externalisierung auslösen. Diese 
war mit Ausnahme von Ionomycin transient und zeitlich begrenzt. Diese Phosphatidylserine-
Translokation korrelierte mit ADAM17-abhängiger ERK1/2 Phosphorylierung und konnte mit 
spezifischen Inhibitoren für ADAM17-Aktivatoren verhindert werden. Diese Korrelation zwi-
schen ADAM17-vermitteltem Shedding und Phosphatidylserin-Externalisierung konnte zusätz-
lich bestätigt werden, durch Verringerung der Phosphatidylserinmenge in Zellen und durch den 
Einsatz von Stilbene-Derivaten, die die Phosphatidylserine-Externalisierung inhibieren. 
ADAM17 enthält, wie andere Phospholipid bindende Proteine, eine polybasische Aminosäure-
gruppe (R625K626XK628). Dieses Motiv liegt in der extrazellulären Membranproximalen Domäne. 
Mittels in vitro Untersuchungen konnte gezeigt werden, dass die Membranproximale Domäne 
von ADAM17 an Phosphatidylserin-Liposomen, nicht jedoch an Phosphatidylcholin-
Liposomen bindet. ADAM17 vermitteltes Shedding konnte im Gegenzug durch die lösliche 
Kopfgruppe von Phosphatidylserine (OPLS) kompetitiv inhibiert werden. Ein Austausch der 
positiv geladenen Aminosäuren durch ungeladene Aminosäuren mittels Mutation verhinderte 
stimuliertes wie konstitutives Shedding von Transmembran-Substraten, ohne jedoch die Proteo-
lyse eines löslichen ADAM Substrats zu beeinflussen. Aus diesen Ergebnissen lässt sich schlie-
ßen, dass Phosphatidylserin Externalisierung der finale „Trigger“ für ADAM17-vermitteltes 
Substrat-Shedding ist. Die Bindung von ADAM17 an die Phosphatidylserin-präsentierende 
Membran bringt möglicherweise die Metalloprotease-Domäne in Position und ermöglicht so das 
Shedding von Transmembran Substraten. Das hier propagierte Modell einer Interaktion zwi-
schen ADAM17 und Phosphatidylserin, beschreibt zum ersten mal den finalen Aktivierungs-
schritt für die ADAM17-vermittelte Proteolyse. In diesem Zusammenhang ist ADAM17 auch 
das erste bekannte Membranprotein, dessen Aktivität durch die Bindung an saure Phospholipide 







% (v/v) Percentage volume/volume 
% (w/v)  Percentage weight/volume 
% (w/w) Percentage weight/weight 
° C Degree in Celsius 
ABB Annexin-binding buffer 
ABC transporter ATP-binding cassette transporters 
ADAM    A disintegrin and metalloprotease 
ADAMDEC-1   ADAM-like decysin 1 
ADAMTS   A disintegrin and metalloprotease with thrombospondin motif  
Amp Ampicillin 
AMP Antimicrobial peptide 
AMPA α-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
ANOVA Analysis of variance 
AP Alkaline phosphatase 
APBS Adaptive Poisson-Boltzmann Solver 
APP Amyloid precursor protein 
AREG Amphiregulin 
ATP    Adenosine triphosphate 
BSA Bovine serum albumin 
BTC Betacellulin 
bzATP Benzoyl-adenosine triphosphate 
CAM Cell adhesion molecule 
CANDIS Conserved ADAM seventeen dynamic interaction sequence 
CD (e.g. CD22) Cluster of differentiation  
Cetux Cetuximab 
co control 
CT Cytoplasmic tail 
CTF C-terminal fragment 
CX3CL1 Fractalkine 
DAG Diacylglycerol 
DNA Deoxyribonucleic acid 
E-, N-, VE-cadherin Epithelial-, neuronal-, vascular endothelial-cadherin 
E. coli Escherichia coli 
ECM Extracellular matrix 
EGF    Epithelial growth factor 
EGFR    Epithelial growth factor receptor 
ELISA Enzyme-linked immunosorbent assay 
ER Endoplasmic reticulum 
ERK1/2 extracellular-signal-regulated kinases 1/2 
Etn Ethanolamine 
FACS Fluorescence-activated cell sorting 
FCS Fetal calf serum 
FGF Fibroblast growth factor 




FITC Fluorescein isothiocyanate 
FS Flexible stalk 
GABA Gamma aminobutyric acid 
GPCR G-protein coupled receptor 
GPI    Glycosylphosphatidylinositol  
Grb2 Growth factor receptor-bound protein 2 
GSL Glycosphingolipid 
h Hour 
HB-EGF Heparin binding EGF-like growth factor 
HEK293T Human embryonic kidney 293T cells 
HIV-1 Human immunodeficiency virus type 1 
HUVEC Human umbilical vein endothelial cell 
IL Interleukin 
ILR Interleukin receptor 
IO Ionomycin 
ITAM Immunoreceptor tyrosine-based activation motif 
ITC Isothermal titration calorimetry 
JAM-A Junctional adhesion molecule A 
l Litre 
L-selectin Leukocyte selectin 
LB medium Lysogeny broth medium 
LCI Life cell imaging 
LPA Lysophosphatidic acid 
LPS Lipopolysaccharide 
LSM Lymphocyte separation medium 
m Meter 
M Molarity 
MAPK Mitogen activated protein kinase 
MEF Murine embryonic fibroblast 




MMP    Matrix metalloprotease 
MPD    Membrane proximal domain  
MPD17   Membrane proximal domain of ADAM17 
Nef Negative Regulatory Factor 
NFκB Nuclear factor kappa-light-chain-enhancer of activated B cells 
NLR Nod-like receptor 
NMDA N-Methyl-D-aspartic acid 
NMR spectroscopy Nuclear magnetic resonance spectroscopy 
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PBS Phosphate buffered saline 
PC Phosphatidylcholine 
PCR Polymerase chain reaction 
PDGF Platelet derived growth factor 
PDGFR Platelet derived growth factor receptor 
PDI Protein disulfide isomerase 
PDK1 Phosphoinositide-dependent kinase 1 
Pen/Strep Penicillin/Streptomycin 
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PKC Protein kinase C 
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PLC Phospholipase C 
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PVDF Polyvenylidene fluoride 
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RNA Ribonucleic acid 
rpm Rounds per minute 
RT Room temperature 
RT-PCR Real-time polymerase chain reaction 
s Second 
S.D. Standard deviation 
S.E. Standard error 
S.E.M. Standard error of the mean 
SAW Surface acoustic wave 
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siRNA small interfering RNA 
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TACE TNF-α converting enzyme (ADAM17) 
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TMD    Transmembrane domain 
TNF-α Tumor necrosis factor alpha 
TNFR Tumor necrosis factor alpha receptor 
VEGF Vascular endothelial growth factor 







Amino acid abbrevations 
Name 3-letter    1-letter 
Alanine Ala    A 
Arginine Arg    R 
Asparagine Asn    N 
Aspartic acid Asp    D 
Cysteine Cys    C 
Glutamic acid Glu    E 
Glutamine Gln    Q 
Glycine Gly    G 
Histidine His    H 
Isoleucine Ile    I 
Leucine Leu    L 
Lysine Lys    K 
Methionine Met    M 
Phenylalanine Phe    F 
Proline Pro    P 
Serine Ser    S 
Threonine Thr    T 
Tyrosine Tyr    Y 
Tryptophan Trp    W 
Valine Val    V   
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